

JOSEPH KNOLL
LIST OF PUBLICATIONS
1950 - 2012

1. Komlós E., Pórszász J., **Knoll J.**: Morphin-Prostigmin Synergismus. Acta Physiol. Acad. Sci. Hung. 1:77-90, 1950
2. **Knoll J.**, Komlós E.: Die analgetische Wirkung des Atropins und sein Synergismus mit Morphin und Prostigmin. Acta Physiol. Acad. Sci. Hung. 2:57-69, 1951
3. **Knoll J.**, Komlós E., Pórszász J.: Analgesic und Cholinesterase-Hemmung. Acta Physiol. Acad. Sci. Hung. 2:479-491, 1951
4. Pórszász J., **Knoll J.**, Komlós E.: Wirkung der Parasympatho-mimetika auf die Analgesie. Acta Physiol. Acad. Sci. Hung. 2:469-477, 1951
5. **Knoll J.**, Komlós E.: Einfluss des Peptons auf die Wirkung der Analgetika und Parasympathomimetika. Acta Physiol. Acad. Sci. Hung. 3:127-136, 1952
6. Komlós E., **Knoll J.**: Synergismus der Analgetika mit Cholin. Acta Physiol. Acad. Sci. Hung. 3:123-126, 1952
7. Komlós E., **Knoll J.**, Tardos L.: Über die Rolle der Eiweissbindung im Synergismus der Analgetika und Parasympathomimetika. Acta Physiol. Acad. Sci. Hung. 4:131-140, 1953
8. Komlós E., **Knoll J.**, Tardos L., Szász V.: Neue Methode zur Messung der lokomotorischen Reaktion von Versuchstieren. Acta Physiol. Acad. Sci. Hung. 4:373-382, 1953
9. **Knoll J.**: Tanulmány a reflexelv alkalmazásáról a nem automatikus jellegű idegtevékenység vizsgálatában. Kandidátusi értekezés, Budapest, 1955 (Ph.D Thesis in Hungarian)
10. **Knoll J.**, Kelemen K., Knoll B.: Experimental studies on the higher nervous activity of animals. I. A method for the elaboration of a non-extinguishable conditioned reflex in the rat. Acta Physiol Hung 8:327-345, 1955
11. **Knoll J.**, Kelemen K., Knoll B.: Experimental studies on the higher nervous activity of animals. II. Differences in the state of function of the cells constituting

the cortical representation of the unconditioned reflex in extinguishable and non-extinguishable conditioned reflexes. *Acta Physiol Hung* 8:347-367, 1955

12. **Knoll J.**, Kelemen K., Knoll B.: Experimental studies on the higher nervous activity of animals. III. Experimental studies on the active conditioned reflex. *Acta Physiol Hung* 8:369-388, 1955

13. **Knoll J.**, Tardos L., Komlós E., Kelemen K., Balázs I.: Untersuchung kardiotonisch wirkender Gewebestoffe. I. Über die kardiotonische Wirkung des Leberperfusates am isolierten Froschherzen. *Acta Physiol Hung* 8:173-186, 1955

14. **Knoll J.**, Tardos L., Komlós E., Kelemen K., Balázs I.: Untersuchung kardiotonisch wirkender Gewebestoffe. II. Herstellung von wirksamen Präparaten und ihre Untersuchung am Froschherzen und Herz-Lungenpräparat von Hund. *Acta Physiol Hung* 8:187-208, 1955

15. **Knoll J.**, Kelemen K., Knoll B.: Experimental studies on the higher nervous activity of animals. IV. A method for elaborating and studying active conditioned feeding reflex. Experimental analysis of differences between active conditioned defensive and feeding reflexes. *Acta Physiol Hung* 9:99-109, 1956

16. **Knoll J.**: Experimental studies on the higher nervous activity of animals. V. The functional mechanism of the active conditioned reflex. *Acta Physiol Hung* 10:89-100, 1956

17. **Knoll J.**, Kelemen K., Knoll B.: Patkányok magasabbrendű idegműködésének kísérletes vizsgálata. I. Az aktív feltételes reflex kialakításának és vizsgálatának módszerei. *MTA V. Oszt. Közl.* 7:221-236, 1956

18. **Knoll J.**: Patkányok magasabbrendű idegműködésének kísérletes vizsgálata. II. Az aktív feltételes reflex mechanizmusának elemzése. *MTA V. Oszt. Közl.* 7:237-267, 1956

19. **Knoll J.**: Über die Steuerung des Ionengleichgewichtes zwischen Zellen und umgebender Flüssigkeit beim isolierten Froschherzen. *Experientia* 12:262-263, 1956

20. Kelemen K., **Knoll J.**, Knoll B.: Untersuchung der Grosshirnhemmung im Zusammenhang mit der activen bedingten Reflextätigkeit. *Acta Physiol Hung Suppl.* 11:19, 1957

21. **Knoll J.**: Experimental studies on the higher nervous activity of animals. VI. Further studies on active reflexes. *Acta Physiol Hung* 12:65-92, 1957

22. **Knoll J.**, Balázs I., Knoll B., Kelemen K.: The cardiotonic effect of EDTA. *Acta Physiol Hung* 12:183-187, 1957

23. **Knoll J.**: Untersuchungen über herzaktive Gewebestoffe. *Klin. Wschr.* 36:141, 1958.

24. **Knoll J.**, Knoll B.: Patkányok magasabbrendű idegműködésének kísérletes vizsgálata. III. Az aktív reflexek osztályozása és a vizsgálati módszerek elvének megbeszélése. MTA V. Oszt. Közl. 8:338-352, 1958
25. **Knoll J.**, Knoll B.: Methode zur Untersuchung der spezifisch depressiven Wirkung von 'Tranquilizern' auf das Zentralnervensystem. Arzneimittel-Forschung 8:330-333, 1958
26. **Knoll J.**, Knoll B.: Módszer tranquilláns anyagok központi idegrendszeri depresszív hatásának vizsgálatára. Kísérletes Orvostudomány 10:337-344, 1958.
27. **Knoll J.**, Kelemen K., Knoll B.: Über die Steuerung des Ionen-gleichgewichtes zwischen Zellen und umgebener Flüssigkeit beim isolierten Froschherzen. Pflügers Arch. Ges. Physiol. 267:150-157, 1958.
28. **Knoll J.**, Kelemen K., Knoll B.: A sejtek és az őket környező folyadék közötti ionegyensúly szabályozása izolált békaszíven. Kísérletes Orvostudomány 10:279-285, 1958.
29. **Knoll J.**: Gyógyszertan. Egészségügyi szakiskolák tankönyve. Medicina, Budapest, pp 1-199, 1958.
30. **Knoll J.**: Kórtan. Tankönyv egészségügyi szakiskolák számára. Medicina, Budapest, pp 1-180, 1958.
31. **Knoll J.**: Neue Methode zur Untersuchung der spezifischen Wirkung tranquilisierender Substanzen auf das Zentralnervensystem. (Die tranquilisierende Wirkung des 1-Piperidino-methyl-tetralon-2) NA 86) und sein Synergismus mit Reserpin.) Arch. Exp. Path. Pharmacol. 236:92-99, 1959.
32. **Knoll J.**, Knoll B.: Methode zur Untersuchung der spezifisch depressiven Wirkung von 'Tranquilizern' auf das Zentralnervensystem. II. Arzneimittel-Forschung 9:633-636, 1959
33. **Knoll J.**, Knoll B.: Tranquilláns anyagok központi idegrendszeri depresszív hatásának összehasonlító vizsgálata. Kísérletes Orvostudomány 11:344-350, 1959.
34. **Knoll J.**: Methods for the evaluating of tranquilizers. In: Neuropsychopharmacology Vol. I. Elsevier, Amsterdam, pp 334-341, 1959.
35. **Knoll J.**, Vajnovszky B.: Motiméter, új érzékeny készülék kis állatok mozgásának mérésére. MTA V. Oszt. Közl. 11:313-328, 1960
36. **Knoll J.**, Nádor K., Knoll B., Nievel J., Heidt J., Magyar K.: Új tranquilláns és görcsgátló hatású béta-aminoketonok. Kísérletes Orvostudomány 12:544-555, 1960
37. **Knoll J.**, Nádor K., Knoll B., Heidt J., Nievel J.: Új tranquilláns és görcsgátló hatású béta-aminoketonok. MTA V. Oszt. Közl. 11:329-340, 1960

38. **Knoll J.**, Knoll B.: A szedato-hipnotikumok és trankvilláns anyagok dekonkondicionáló hatásának differenciálása. MTA V. Oszt. Közl. 11:145-153, 1960
39. **Knoll J.**: Über die potenzierende Wirkung des Reserpin gegenüber dem Elektroschock und ihre Hemmung mit 1-Piperidino-methyltetralon-2. Arch. Exp. Path. Pharmacol. 238:114-115, 1960.
40. **Knoll J.**, Kelemen K., Knoll B., Nievel J.: Görcsokozó hidrazidok centrális hatásának kísérletes elemzése. MTA V. Oszt. Közl. 12:157, 1960
41. **Knoll J.**: The quantitative assesment of psychostimulant and tranquillizing effect with new method. In: Techniques for the Study of Psychotropic Drugs. (Ed.: G. Tonini), Societa Tipografica Modenese, Modena, p 72-74, 1960.
42. **Knoll J.**: The deconditioning effect of some beta-aminoketones a new group of tranquillizers. In: Neuropsychopharmacology. Vol. II. (Eds.: P.B. Bradley, P. Deniker, C. Radouco-Thomas), Elsevier, Amsterdam, p 162, 1960.
43. Kelemen K., Magyar K., **Knoll J.**: Electroencephalographical discrimination between sedato-hypnotic and major-tranquillizing effects in rats with non-extinguishable conditioned reflexes. Biochem. Pharmacol 8:59-64, 1961
44. Kelemen K., Longo V.G., **Knoll J.**, Bovet D.: The EEG arousal reaction in rats with extinguishable and non-extinguishable conditioned reflexes. EEG Clin. Neurophysiol 13:745-751, 1960
45. Kelemen K., Longo V.G., **Knoll J.**, Bovet D.: Különbségek a feltételes ingerrel kiváltott "ébredési reakció" időtartamában kialakuló és ki nem alvó feltételes reflexes patkányokon. MTA V. Oszt. Közl. 12:285-293, 1961
46. **Knoll J.**: A pszichofarmakológia néhány aktuális problémája. MTA V. Oszt. Közl. 12:171-204, 1961
47. **Knoll J.**, Vajnovszky B.: Motimeter a new sensitive apparatus for the quantitative measurement of hypermotility caused by psychostimulants. Arch. int. Pharmacodyn. Ther. 130:141-154, 1960
48. **Knoll J.**, Kelemen K., Knoll B., Nievel J.: Experimental analysis of the central effect of convulsive hydrazides. Acta Physiol Hung 19:169-178, 1961
49. **Knoll J.**, Knoll B.: Reserpine: Modification of its tranquilizer effect and analysis of its central mode of action. Arch. int. Pharmacodyn. Ther. 133:310-326, 1961
50. **Knoll J.**, Knoll B.: A reszerpin trankvilláns hatásának modifikálása és centrális hatásmódjának elemzése. Kísérletes Orvostudomány 13:457-467, 1961

51. **Knoll J.**, Nádor K., Knoll B., Heidt J., Nievel J.: Beta-amino-ketones a new group of tranquilizers. Arch. int. Pharmacodyn. Ther. 130:155-167, 1961
52. **Knoll J.**: Az aktív reflexek elmélete. A magasabbrendű alkalmazkodás (magasabbrendű idegtevékenység) és elemi adaptáció néhány fundamentális mechanizmusának elemzése. Tudományok doktora disszertáció. Budapest, 1961. (Doctor of Science Thesis)
53. **Knoll J.**: Pszichofarmakonok jelentősége a magasabbrendű idegtevékenység élettani mechanizmusainak elemzésében. MTA V. Oszt. Közl. 13:423-444, 1962
54. **Knoll J.**, Kelemen K., Knoll B.: Celluline: a fundamental highly specific substance of the cell membrane. Proceedings of the Int. Union of Physiological Sciences Vol II. p 556, 1962
55. **Knoll J.**: Módszer pszichofarmakonok hatásának mérésére és a hatásmód alapján történő differenciálásra. (Módosított ugrásteszt). MTA V. Oszt. Közl. 14:223-236, 1963
56. **Knoll J.**, Knoll B.: A reszerpin trankvilláns hatásának kumulatív jellege és a kumuláció farmakológiai gátlásának lehetőségei. MTA V. Oszt. Közl. 14:203-214, 1963
57. **Knoll J.**, Knoll B.: The cumulative nature of the reserpine effect and the possibilities of inhibiting cumulation pharmacologically. Arch. int. Pharmacodyn. Ther. 148:200-216, 1964
58. **Knoll J.**, Ecsery Z., Nievel J., Knoll B.: Phenylisopropylmethyl-propinylamine HCl (E-250) egy új hatásspektrumu pszichoenergetikum. MTA V. Oszt. Közl. 15:231-238, 1964
59. **Knoll J.**: Cellulin: egy specifikus hatásmódú kardiotonikus hatású szöveti anyag. I. A cellulin létezésének kimutatása specifikus kardiotonikus hatása alapján. MTA V. Oszt. Közl. 16:311-326, 1965
60. **Knoll J.**, Kelemen K., Knoll B.: Cellulin: egy specifikus hatásmódú kardiotonikus hatású szöveti anyag. II. A cellulin szerepe az izolált békaszív kálium túlsúlyhoz történő alkalmazkodásában. MTA V. Oszt. Közl. 16:327-338, 1965
61. **Knoll J.**, Scheiber E., Magyar K., Hadházy P., Friedmann T.: Cellulin: egy specifikus hatásmódú kardiotonikus hatású szöveti anyag. III. A cellulintartalmú preparátumok előállítására és biológiai titrálásra béka- és emlős-szíven. MTA V. Oszt. Közl. 16:339-349, 1965
62. Kelemen K., Kecskeméti V., **Knoll J.**: Cellulin: egy specifikus hatásmódú kardiotonikus hatású szöveti anyag. IV. A cellulin specifikus hatásának vizsgálata békaszív kamrán transzmembrán potenciál mérések segítségével. MTA V. Oszt. Közl. 16:351-358, 1965

63. **Knoll J.**, Ecsery Z., Kelemen K., Nievel J., Knoll B.: Phenylisopropylmethylpropinylamine (E-250) a new psychic energizer. Arch. int. Pharmacodyn. Ther. 155:154-164, 1965
64. **Knoll J.**, Vizi E.S., Ecsery Z.: Pszichotomimetikus methylamphetamin származékok. MTA V. Oszt. Közl. 16:413-420, 1965
65. **Knoll J.**, Vizi E.S., Knoll B., Somogyi Gy.: A reszerpin hatásmódjának elemzése. MTA V. Oszt. Közl. 16:227-238, 1965
66. **Knoll J.**: The specific activation of the CNS and its significance in psychopharmacological research. In: Pharmacology of conditioning, learning and retention. (Ed.: M.J. Michelson), Pergamon Press, London, p 221, 1965.
67. **Knoll J.**: Gyógyszertan. Medicina, Budapest, pp 1-842, 1965. (Handbook of Pharmacology, First edition)
68. Hadházy P., Friedmann T., Scheiber E., **Knoll J.**: Cardiotonic action of celluline on mammalian heart preparations. Acta Physiol. Hung. 29:339-400, 1966
69. **Knoll J.**: Issekutz Béla. Orvosi Hetilap 107:273, 1966 (Laudatio, 80th birthday)
70. **Knoll J.**, Vizi E.S., Ecsery Z.: Psychotomimetic methylamphetamine derivatives. Arch. int. Pharmacodyn. Ther. 159:442-451, 1966
71. **Knoll J.**, Vizi E.S., Knoll B., Somogyi G.: Analysis del mecanismo de la reserpina. Pren. Méd. Argent. 53:568-577, 1966
72. **Knoll J.**, Vizi E.S., Knoll B., Somogyi G.: A p-bromo-metilamphetamin (V-111), egy pszichotomimetikus fenilalkilamin farmakológiája. MTA V. Oszt. Közl. 18:40-49, 1967
73. **Knoll J.**, Vizi E.S., Somogyi G.: A phenyl-isopropyl-methyl-propinylamine (E-250) tyramin-antagonista hatása. MTA V. Oszt. Közl. 18:33-37, 1967
74. Magyar K., Vizi E.S., Ecsery Z., **Knoll J.**: A fenil-izopropil-metil-propinilamin (E-250) optikai izomerjeinek összehasonlító farmakológiai vizsgálata. Kísérletes Orvostudomány 19:404-412, 1967
75. Magyar K., Vizi E.S., Ecsery Z., **Knoll J.**: Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiol. Hung. 32:377-387, 1967
76. **Knoll J.**: Screening and grouping of psychopharmacologic agents. In: Animal and Clinical Pharmacological Techniques in Drug Evaluation. (Ed.: P.E. Siegler), Year Book Medical Publishers Inc. Chicago, pp 305-321, 1967.
77. **Knoll J.**: Pharmacological control of central nervous activation. In: Recent development of neurology in Hungary. Results in neuroanatomy, neurophysiology,

neuropathophysiology and neuropharmacology. (Ed.: Lissák K.), Akadémiai Kiadó, Budapest, pp 72-97, 1967.

78. Fürst S., **Knoll J.**: Újabb adatok a morfintolerancia kérdéséhez. *Herba Hung.* 7:53-58, 1968

79. **Knoll J.**: Pszichofarmakonok screenelésének néhány problémája. *Orvostudomány* 19:331-340, 1968

80. **Knoll J.**, Vizi E.S., Somogyi G.: Phenyl-isopropyl-methyl-propinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine. *Arzneim.-Forsch.* 18:109-112, 1968

81. Vizi E.S., Knoll B., **Knoll J.**: Interaction between phenylalkylamine derivatives and reserpine. *Int. J. Neuropharm.* 7:503-509, 1968

82. **Knoll J.**: Gyógyszertan I-II. 2. átdolgozott kiadás. *Medicina*, Budapest, pp 1-927, 1968 (Handbook of Pharmacology 2nd revised edition)

83. **Knoll J.**: Some new aspects in the pharmacology of phenylalkylamines. In: IV. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia (Eds.: B. Dumbovich, G. Fekete, K. Raáb), Publishing House of the Hungarian Academy of Sciences, Budapest, pp 23-40, 1968

84. **Knoll J.**: The specific action of tetrahydroethoxy-dibenzo-isoquinolisine on the central nervous system. In: IV. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia (Eds.: B. Dumbovich, G. Fekete, K. Raáb), Publishing House of the Hungarian Academy of Sciences, Budapest, pp 55-58, 1968

85. Vizi E.S., Szentmiklósi P., **Knoll J.**: Magengeschwürhemmende Wirkung von Bispan^R an Ratten. 4th Hungarian Conference for Therapy and Pharmacological Research. In: IV. Conferentia Hungaria pro Therapia et Investigatione in Pharmacologia. (Eds.: B. Dumbovich, G. Fekete, K. Raáb), Publishing House of the Hungarian Academy of Sciences, Budapest, pp 267-268, 1968

86. **Knoll J.**: Szovetszko-vengerszkoé naucsnoe szotrudnicsesztvo v oblaszti farmakoterapeuticsszkih isszledovanij. *Veng. Farmakoter.* 1:4-5, 1969

87. **Knoll J.**, Mészáros Z., Szentmiklósi P., Fürst S.: Az 1,6-dimethyl-3-carbetoxy-4-oxo-6,7,8,9-tetrahydrohomopyrimidazol methylsulphat (MZ-144), egy új erőshatású nem kábító fájdalomcsillapító farmakológiája. I. A vegyi szerkezet és hatás néhány lényeges összefüggése a homopyrimidazol analgetikumok esetében és az MZ-144 kiválasztása. *Orvostudomány* 20:361-369, 1969

88. **Knoll J.**, Fürst S., Mészáros Z.: Az 1,6-dimethyl-3-carbetoxy-4-oxo-6,7,8,9-tetrahydrohomopyrimidazol methylsulphat (MZ-144), egy új erőshatású nem kábító fájdalomcsillapító farmakológiája. II. Az MZ-144 toxicitásának és analgetikus hatásának elemzése kábító és nem kábító fájdalomcsillapítókkal összehasonlítva. *Orvostudomány* 20:371-395, 1969

89. **Knoll J.**, Fürst S., Mészáros Z.: Az 1,6-dimethyl-3-carbetoxy-4-oxo-6,7,8,9 tetrahydrohomopyrimidazol methylsulphat (MZ-144), egy új erőshatású nem kábító fájdalomcsillapító farmakológiája. III. Az MZ-144 centrális és perifériás hatásainak elemzése. *Orvostudomány* 20:398-415, 1969
90. **Knoll J.**, Magyar K., Bánfi D.: Az 1,6-dimethyl-3-carbetoxy-4-oxo-6,7,8,9 tetrahydrohomopyrimidazol methylsulphat (MZ-144), egy új erőshatású nem kábító fájdalomcsillapító farmakológiája. IV. Az MZ-144 szervezeten belüli sorsának vizsgálata. *Orvostudomány* 20:417-432, 1969
91. **Knoll J.**: The Theory of Active Reflexes. An Analysis of some Fundamental Mechanisms of Higher Nervous Activity. Pages 1-131, Publishing House of the Hungarian Academy of Sciences, Budapest, Hafner Publishing Company, New York 1969
92. Fürst S., Mészáros Z., **Knoll J.**: Pharmacology of MZ-144, a new homopyrimidazol derivative. *Acta Physiol. Hung.* 37:189-190, 1970
93. Garamvölgyi M., Vizi E.S., **Knoll J.**: Feszülés hatása a gerinces simaizom ultrastrukturájára. *Orvostudomány* 21:201-212, 1970
94. **Knoll J.**: A cellulinek: specifikus hatásmódú, kardiotonikus hatású endogén anyagok. *Orvostudomány* 21:271-324, 1970
95. **Knoll J.**: Gyógyszerkutatásunk fejlődése a felszabadulás óta. *Gyógyszereink* 20:146-150, 1970
96. **Knoll J.**, Vizi E.S.: Inhibition of the effects of LSD and p-bromo-methamphetamine (V-111) by p-chlorophenylalanine. *Pharm. Res. Comm.* 2:67-70, 1970
97. **Knoll J.**, Vizi E.S.: Presynaptic inhibition of acetylcholine release by endogenous noradrenaline at high rate of stimulation. *Br. J. Pharmacol.* 40:554, 1970
98. **Knoll J.**, Vizi E.S.: Cross-tolerance between para-bromo-methamphetamine (V-111) and LSD-25. *Pharmacology* 4:278-286, 1970
99. **Knoll J.**, Vizi E.S., Knoll B.: Pharmacological studies on para-bromo-methamphetamine (V-111) and LSD. *Acta Physiol. Hung.* 37:151-170, 1970
100. Magyar K., **Knoll J.**: Distribution of ¹⁴C-phenylisopropyl-methyl-propynilamine (¹⁴C-E-250) estimated by whole body autoradiography. *Acta Physiol. Hung.* 37:150, 1970

101. Magyar K., **Knoll J.**: Effect of phenyl-isopropyl-methyl-propinylamine (Deprenaline) on the subcellular distribution of ³H-noradrenaline. *Acta Physiol. Hung.* 37:414, 1970
102. Sátyory É., Magyar K., **Knoll J.**: Estimation of monoamine oxidase activity by ¹⁴C-tyramine. *Acta Physiol. Hung.* 37:207-208, 1970
103. Skolnik J., Magyar K., **Knoll J.**: Fate of the analgesic homopyrimidazols (MZ-compounds) in the organism. *Acta Physiol. Hung.* 37:207-208, 1970
104. Vizi E.S., **Knoll J.**: Contraction force (P) and velocity dP/dt elicited by endogenous acetylcholine in the longitudinal smooth muscle preparation of the guinea pig ileum. *Acta Physiol. Hung.* 37:451, 1970
105. Vizi E.S., Somogyi G., **Knoll J.**: Pharmacokinetic analysis of drugs with central nervous effects. *Acta Physiol. Hung.* 37:213-214, 1970
106. **Knoll J.**, Vizi E.S., Knoll B.: Development of tolerance to some substituted amphetamines in rats, cats and rabbits. *Excerpta Medica Int. Congr. Series No. 220.* pp 50-55, 1970.
107. **Knoll J.**: Psychotomimetic effects of amphetamines. In: *Amphetamines and related compounds* (Eds.: E.Costa, S. Garattini), Raven Press, New York, pp 761-780, 1970
108. Fürst S., Kelemen K., **Knoll J.**: Comparative pharmacology of some azidomorphine derivatives. *Acta Physiol. Hung.* 39:265-266, 1971
109. Garamvölgyi N., Vizi E.S., **Knoll J.**: The regular occurrence of thick filaments in stretched mammalian smooth muscle. *J. Ultrastructure Res.* 34:135-143, 1971
110. Garamvölgyi N., Vizi E.S., **Knoll J.**: Thick myofilaments in vertebrate smooth muscle. *Acta Physiol. Hung.* 39:173-174, 1971
111. Illés P., Vizi E.S., **Knoll J.**: Effects of reserpine on central and peripheral acetylcholine level. *Acta Physiol. Hung.* 39:262-25, 1971
112. Jóna G., Sátyory É., Magyar K., **Knoll J.**: Effect of p-bromo-methamphetamine (V-111) on 5-HT metabolism. *Acta Physiol. Hung.* 39:265, 1971
113. Kecskeméti V., Kelemen K., **Knoll J.**: Interaction of celluline and tetrodoxin on the sodium-transporting system of heart. *Acta Physiol. Hung.* 39:247, 1971
114. **Knoll J.**: Gyógyszerkutatásunk fejlődése a felszabadulás óta. *Magyar Tudomány* 16:314-318, 1971
115. **Knoll J.**, Fürst S., Kelemen K.: Az azidomorfin (6-deoxy-6-azido-dihydroizomorfin) farmakológiája. *Orvostudomány* 22:265-284, 1971

116. **Knoll J.**, Mészáros Z., Szentmiklósi P., Fürst S.: The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methyl-sulphate (MZ-144), a new potent, non-narcotic analgesic. I. Some basic correlations between the chemical structure and activity of homopyrimidazol analgesics. Selection of MZ-144. *Arzneim.-Forsch.* 21:717-719, 1971
117. **Knoll J.**, Fürst S., Mészáros Z.: The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methyl-sulphate (MZ-144), a new potent, non-narcotic analgesic. II. Toxicity and analgesic effect of MZ-144 compared to narcotic and non-narcotic analgesics. *Arzneim.-Forsch.* 21:719-727, 1971
118. **Knoll J.**, Fürst S., Mészáros Z.: The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methyl-sulphate (MZ-144), a new potent, non-narcotic analgesic. III. Analysis of the central and peripheric effects. *Arzneim.-Forsch.* 21:727-733, 1971
119. **Knoll J.**, Magyar K., Bánfi D.: The pharmacology of 1,6-dimethyl-3-carbethoxy-4-oxo-6,7,8,9-tetrahydro-homopyrimidazol-methyl-sulphate (MZ-144), a new potent, non-narcotic analgesic. IV. The fate of MZ-144 within the organism. *Arzneim.-Forsch.* 21:733-738, 1971
120. **Knoll J.**, Vizi E.S.: Effect of frequency of stimulation on the inhibition by noradrenaline of the acetylcholine output from parasympathetic nerve terminals. *Brit. J. Pharmacol.* 41:263-272, 1971
121. Magyar K., **Knoll J.**: Effect of amphetamine derivatives on the subcellular distribution of H-noradrenaline. *Acta Physiol. Hung.* 39:264-265, 1971
122. Sátorj É., Magyar K., **Knoll J.**: Substrate and inhibitor specificity of monoamines. *Acta Physiol. Hung.* 39:150-151, 1971
123. Skolnik J., Kelemen K., **Knoll J.**: Action of celluline on the isolated frog heart. *Acta Physiol. Hung.* 39:173, 1971
124. Somogyi G., Vizi E.S., **Knoll J.**: Action of cholinomimetics and cholinolytics on the isolated vas deferens stimulated by single pulse. *Acta Physiol. Hung.* 39:261, 1971
125. Vizi E.S., **Knoll J.**: The effect of sympathetic nerve stimulation and guanethidine on parasympathetic neuroeffector transmission; the inhibition of acetylcholine release. *J. Pharm. Pharmacol.* 23:918-925, 1971
126. Vizi E.S., Somogyi G., Fürst S., **Knoll J.**: Inhibitory effect of guanethidine on cholinergic and adrenergic transmission. *Acta Physiol. Hung.* 39:262-263, 1971
127. Zsilla G., Scheiber E., Magyar K., **Knoll J.**: Metabolism of homopyrimidazol analgesics. *Acta Physiol. Hung.* 39:266, 1971

128. **Knoll J.**, Vizi E.S., Magyar K.: Pharmacological studies on some cerebral effects of amphetamines. Results of Neuroanatomy, Budapest, p 167-217, 1971.
129. Fürst S., Kelemen K., Szentmiklósi P., **Knoll J.**: A detailed analysis of the analgesic action of MZ-108, a new homopyrimidazol derivative. In: V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. (Ed.: G.P. Leszkovszky), Publishing House of the Hung. Acad. Sci., Budapest, pp 65-69, 1971
130. **Knoll J.**: Gyógyszertan I-II. 3. átdolgozott kiadás. Medicina, Budapest, pp 1-986, 1971 (Handbook of Pharmacology 3rd revised edition)
131. **Knoll J.**: Homopyrimidazols, a new group of analgesics with unique spectrum of activity. In: V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. (Ed.: G.P. Leszkovszky), Publishing House of the Hung. Acad. Sci., Budapest, pp 27-41, 1971
132. **Knoll J.**, Kelemen K., Knoll B.: A psychopharmacological approach to a possible synaptic memory mechanism. In: Biology of Memory. (Ed.: g. Ádám), Symposia Biologica Hungarica, Vol. 10., Publishing House of the Hung. Acad. Sci., Budapest, pp 247-253, 1971
133. Magyar K., Skolnik J., **Knoll J.**: Radiopharmacological analytical studies with Deprenil ¹⁴C. In: V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. (Ed.: G.P. Leszkovszky), Publishing House of the Hung. Acad. Sci., Budapest, pp 103-109, 1971
134. Somogyi G., Vizi E.S., **Knoll J.**: Some new data on the pharmacology of Deprenil (E-250). In: V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. (Ed.: G.P. Leszkovszky), Publishing House of the Hung. Acad. Sci., Budapest, pp 97-102, 1971
135. Vizi E.S., Kelemen K., **Knoll J.**: Pharmacology of N1-O-carboxy-phenyl-N2-p-(2-methyl-aminopropyl-1)-phenyl-acetamide (I-1703), a new type psychostimulant. In: V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. (Ed.: G.P. Leszkovszky), Publishing House of the Hung. Acad. Sci., Budapest, pp 165-170, 1971
136. Kelemen K., Kecskeméti V., **Knoll J.**: Cellulin-A hatásának vizsgálata macskaszívfülcén transzmembrán potenciálmérések segítségével. Orvostudomány 23, 231-241, 1972
137. Kelemen K., Kecskeméti V., **Knoll J.**: Cellulin-A hatása a szívizomsejtek "gyors" és "lassú" nátrium-csatornájára. Orvostudomány 23, 357-389, 1972
138. Kelemen K., Skolnik J., **Knoll J.**: Cellulin-A hatása a szívszövet nátriumcseréjére. Orvostudomány 23, 391-402, 1972
139. **Knoll J.**, Magyar K.: Some puzzling effects of monoamine oxidase inhibitors.

In: Monoamine Oxidase-New Vistas. Advances in Biochemical Psychopharmacology. Vol.5. (Eds.: E. Costa, M. Sandler), Raven Press, New York, pp. 393-408, 1972.

140. **Knoll J.**, Magyar K.: Monoaminooxidáz-bénítók farmakológiájának aktuális problémái. Orvostudomány 23, 87-97, 1972

141. **Knoll J.**, Magyar K., Vizi E.S., Knoll B., Török T.L., Jóna G.: Az agyi szerotonin szerepe a para-brom-metamfetamin (V-111) farmakológiai hatásaiban. Orvostudomány 23, 99-120, 1972

142. **Knoll J.**, Somogyi G., Illés P., Vizi E.S.: Acetylcholine release from isolated vas deferens of the rat. N-S Arch. Pharmacol. 274:198-202, 1972

143. Magyar K., Sátorj É., Jóna G., **Knoll J.**: The biochemical mode of action of p-bromo-methamphetamine (V-111). Acta Physiol. Hung. Suppl. 41:356, 1972.

144. Mészáros Z., **Knoll J.**, Szentmiklósi P., Dávid Á., Horváth G., Hermez I.: Synthesis of new analgetic homopyrimidazols. Arzneimittel.-Forsch. 21:815-829, 1972

145. Vizi E.S., Bertaccini G., Impicciatore M., **Knoll J.**: Acetylcholine-releasing effect of gastrin and related polypeptides. Europ. J. Pharmacol. 17:175-178, 1972

146. Vizi E.S., Illés P., Rónai A., **Knoll J.**: The effect of lithium on acetylcholine release and synthesis. Neuropharmacology 11:521-530, 1972

147. Zsilla G., Magyar K., **Knoll J.**: Metabolism of ^{14}C Probon^R (^{14}C -MZ-144) and the radiochromatographic identification of its metabolites. Acta Physiol. Hung. Suppl. 41:367-368, 1972.

148. **Knoll J.**: Modulation of learning and retention by amphetamines. 5th Int. Congr. on Pharmacology, San Francisco, Abstracts of invited presentations, pp 248-249, 1972

149. Knoll B., Vizi E.S., **Knoll J.**: Comparison of the psychotomimetic effect of p-bromo-methyl-amphetamine (V-111) and LSD. In: First International Congress on Higher Nervous Activity. (Ed.: C.L. Cazzullo), Pacini, Pisa, pp 433-4

150. **Knoll J.**, Vizi E.S., Magyar K.: Pharmacological studies on some central effects of amphetamines. In: Recent developments on neurobiology in Hungary. III. Results in neuroanatomy, neurophysiology, neuropathology and neuropharmacology. (Ed.: K. Lissák), Publishing House of the Hung. Acad. Sci., Budapest, pp. 167-217, 1972

151. Vizi E.S., **Knoll J.**: The mechanism of acetylcholine release by nicotine. Posebna Izdanja XVII. Odeljenje Medicinskih Nauka. Kniga 4:131-150, 1972

152. Garamvölgyi N., Vizi E.S., **Knoll J.**: The site and state of myosin in intestinal smooth muscle. Phil. Trans. R. Soc. Lond. B. 43:180-189, 1973

153. Hadházy P., Illés P., **Knoll J.**: The effects of PGE₁ on responses to cardiac vagus nerve stimulation and acetylcholine release. *Europ. J. Pharmacol.* 23:251-255, 1973
154. Hadházy P., **Knoll J.**: A prostaglandin E₁ (PGE₁) hatása a myocardiális neurokémiai transzmisszióra. *Orvostudomány* 24:81-88, 1973
155. Illés P., Hadházy P., Torma Z., Vizi E.S., **Knoll J.**: The effect of number of stimuli and rate of stimulation on the inhibition by PGE₁ of adrenergic transmission. *Europ. J. Pharmacol.* 24:29-36, 1973
156. Illés P., Torma Z., Vizi E.S., **Knoll J.**: A PGE₁ inger tartamtól és ingerlési frekvenciától függő gátló hatása a szimpatikus transzmisszióra. *Orvostudomány* 24:89-98, 1973
157. Kalász H., **Knoll J.**: A new two column system for recycling chromatography. *Science Tools* 20:15-16, 1973, IF: 0
158. Kecskeméti V., Kelemen K., **Knoll J.**: Prostaglandin E₁ hatásának vizsgálata izolált emlős-szív készítményeken. *Kísérletes Orvostudomány* 25:184-192, 1973
159. Kecskeméti V., Kelemen K., **Knoll J.**: Effect of prostaglandin E₁ (PGE₁) on the cardiac transmembrane potentials. *Europ. J. Pharmacol.* 24:289-295, 1973
160. **Knoll J.**: Azidomorphine and Rymazolium. An approach to the ideal analgesic. *Pharm. Res. Comm.* 5:175-191, 1973
161. **Knoll J.**, Fürst S., Vizi E.S.: Kinetic parameters of new narcotic agonist, azidomorphine. *Pharmacology* 10:354-362, 1973
162. **Knoll J.**, Fürst S., Kelemen K.: The pharmacology of azidomorphine and azidocodeine. *J. Pharm. Pharmacol.* 25:929-939, 1973
163. **Knoll J.**, Zsilla G.: Possible mechanism of the low tolerance capacity of azidomorphine and azidocodeine. *Biochem. Pharmac.* 23:745-750, 1973
164. Magyar K., **Knoll J.**: Distribution of 1,6-dimethyl-3-carbetoxy-4-oxo-6,7,8,9-tetrahydrol (MZ-144, Probon). *Acta Physiol. Hung.* 43:353-358, 1973
165. Magyar K., Zólyomi G., Bánfi D., **Knoll J.**: A Halidor szervezeten belüli sorsának tanulmányozása pozicionálisan jelzett radioizomerek segítségével. *Acta Pharmaceutica Hung.* 43:103-110, 1973
166. Török T.L., Vizi E.S., **Knoll J.**: Különböző amfetaminok szerkezete, valamint az alpanyagcserét és hőmérsékletet fokozó hatása közötti összefüggés vizsgálata. *Acta Pharmaceutica Hung.* 43:126-136, 1973
167. Vizi E.S., Bertaccini G., Impicciatore M., **Knoll J.**: Evidence that acetylcholine released by gastrin and related polypeptides contributes to their effect on gastrointestinal motility. *Gastroenterology* 64:268-277, 1973

168. Vizi E.S., Garamvölgyi N., **Knoll J.**: Thick filament in guinea pig vas deferens smooth muscle. *Acta Biochim. et Biophys. Acad. Sci. Hung.* 8:73-76, 1973
169. Vizi E.S., Somogyi G., Hadházy P., **Knoll J.**: Effect of duration and frequency of stimulation on the presynaptic inhibition of alpha adrenoceptor stimulation of the adrenergic transmission. *N-S Arch. Pharmacol.* 280:79-91, 1973
170. Vizi E.S., Török T.L., **Knoll J.**: "Prostaglandin" E₁ és E₂ hatásmódjának vizsgálata "Sucrose-gap" technika segítségével taenia-coli preparátumon. *Orvostudomány* 24:99-110, 1973
171. Zólyomi G., Bánfi D., Magyar K., **Knoll J.**: A Halidor pozicionális jelölése különféle radioizotópokkal és az izotópipizomerek alkalmazása a metabolitok rétegekromatográfiás vizsgálatában. *Acta Pharmaceutica Hung.* 43:97-102, 1973
172. **Knoll J.**: The pharmacology of azidomorphine and azidocodeine. Reported to the Committee on Problems of Drug Dependence. 35th Meeting of National Academy of Sciences-National Academy of Engineering National Research Council. Chapel Hill, North Carolina, pp 188-214, 1973
173. Kecskeméti V., Kelemen K., **Knoll J.**: Microelectrophysiological analysis of the cardiac effect of catecholamines. In: Symposium on drugs and heart metabolism. (Eds.: J. Knoll, L. Szekeres, Gy. Papp), Akadémiai Kiadó, Budapest, pp 157-164, 1973
174. Kelemen K., Kecskeméti V., Skolnik J., **Knoll J.**: Microelectrophysiological analysis of the cardiac effect of celluline-A. In: Symposium on drugs and heart metabolism. (Eds.: J. Knoll, L. Szekeres, Gy. Papp), Akadémiai Kiadó, Budapest, pp 165-177, 1973
175. **Knoll J.**, Magyar K., Vizi E.S., Török T.L., Sátyory É., Jóna G.: The role of brain serotonin in the pharmacological effects of p-bromo-methamphetamine (V-111). In: Symposium on pharmacological agents and biogenic amines in the central nervous system. (Eds.: J. Knoll, K. Magyar), Akadémiai Kiadó, Budapest, pp 13-36, 1973
176. Magyar K., Sátyory É., **Knoll J.**: Selective inhibition of monoamine oxidase by Deprenyl. In: Symposium on pharmacological agents and biogenic amines in the central nervous system. (Eds.: J. Knoll, K. Magyar), Akadémiai Kiadó, Budapest, pp 107-122, 1973
177. Illés P., Vizi E.S., **Knoll J.**: Adrenergic neuroeffector junctions sensitive and insensitive to the effect of PGE₁. *Pol. J. Pharmacol. Pharm.* 26:127-136, 1974
178. Kalász H., Nagy J., **Knoll J.**: Gel-chromatographic properties of calcium ions. *Zeitschrift Analytical Chemistry* 272:22-24, 1974

179. Kecskeméti V., Kelemen K., **Knoll J.**: Microelectrophysiological analysis of the cardiac effect of prostaglandin E₂. *Pol. J. Pharmacol. Pharm.* 26:171-176, 1974
180. Kelemen K., Kecskeméti V., **Knoll J.**: Possible role of prostaglandins in cardiac electrogenesis. *Pol. J. Pharmacol. Pharm.* 26:177-186, 1974
181. **Knoll J.**, Makleit S., Friedmann T., Hársing L.G.Jr., Hadházy P.: Circulatory, respiratory and antitussive effects of azidomorphine and related substances. *Arch. int. Pharmacodyn.* 210:241-249, 1974
182. **Knoll J.**, Zséli J., Rónai A., Vizi E.S.: Effect of azidomorphine and related substances on the intestinal motility. *Pharmacology* 12:283-289, 1974
183. Magyar K., Sátyor É., Mészáros Z., **Knoll J.**: The monoamine oxidase inhibitory effect of new homopyrimidazole derivatives. *Med. Biol.* 52:384-389, 1974
184. Magyar K., Sátyor É., Mészáros Z., **Knoll J.**: Új homopyrimidazol származékok monoaminooxidáz bénító hatása. *Orvostudomány* 25:143-150, 1974
185. Vizi E.S., Bertaccini G., Impicciatore M., Mantovani P., Zséli J., **Knoll J.**: Structure-activity relationship of some analogues of gastrin and cholecystokinin on intestinal smooth muscle of the guinea pig. *N-S Arch. Pharm.* 284:233-243, 1974
186. Fürst S., **Knoll J.**: Pharmacokinetic studies on interaction of Rymazolium and morphine-like drugs. In: *Drug interactions.* (Eds.:P.L. Morselli, S. Garattini, S.N. Cohen), Raven Press, New York, pp 277-284, 1974
187. Knoll B., Held K., **Knoll J.**: Rapid screening of drug actions on learning and memory. In: *Symposium on Pharmacology of Learning and Retention.* (Ed.: B. Knoll), Akadémiai Kiadó, Budapest, pp 43-47, 1974
188. Bognár R, Makleit S, **Knoll J**, Berényi S, Horváth G: Tozil-, illetve mezil származékok reakcióinak vizsgálata a morfinsorban, XIII. morfin-alkaloidok azidoszármazékai. *Kémiai Közlemények* 44. kötet 1975, p.1-10
189. Gyires K, **Knoll J.**: Inflammation and writhing syndrome inducing effects of PGE₁, PGE₂ and the inhibition of these actions. *Pol. J. Pharmacol. Pharm.* 27:257-264, 1975
190. Kalász H, Nagy J, **Knoll J.**: Recycling gel chromatography of phenolic compounds. II. Numerical calculation of optimal number of cycles and resolution. *J. Chromatogr.* 107:35-42, 1975
191. **Knoll J.**: Predictive values of pharmacological models to study opiate dependence. *Neuropharm.* 14:921-926, 1975
192. **Knoll J**, Zsilla G, Makleit S.: The metabolism of azidomorphine in the rat. *Med. Biol.* 53:501-504, 1975

193. **Knoll J**, Fürst Zs, Makleit S.: The pharmacology of 14-hydroxyazidomorphine. *J. Pharm. Pharmacol.* 27:99-105, 1975
194. **Knoll J**, Illés P, Torma Z.: The effect of PGE₂ on contraction delay and velocity of the field stimulated guinea pig vas deferens. *Neuropharm.* 14:317-324, 1975
195. **Knoll J**, Knoll B.: p-Bromo-methamphetamine (V-111) induced improvement of learning ability in rats. *Int. J. Neurology* 10:198-221, 1975
196. **Knoll J**, Makleit S., Friedmann T., Hársing L., Hadházy P.: Az azidomorfin és származékainak hatása a keringésre, légzésre és köhögésre. *Orvostudomány* 26:89-95, 1975
197. **Knoll J**, Zséli J., Rónai A., Vizi E.S.: Az azidomorfin és származékainak hatása a bélmotilitásra. *Orvostudomány* 26:97-101, 1975
198. **Knoll J**, Fürst Zs., Makleit S.: A 14-hidroxiazidomorfin farmakológiája. *Orvostudomány* 26:103-110, 1975
199. **Knoll J**, Magyar K., Makleit S., Zólyomi G., Zsilla G.: Az azidomorfinok sorsa a szervezetben. *Orvostudomány* 26:111-127, 1975
200. **Knoll J**, Magyar K., Zólyomi G.: Absorption, distribution and elimination of azidomorphine and related substances. *Acta Physiol. Hung.* 46:163-172, 1975
201. **Knoll J**: Azidomorfinok és homopirimidazolok. Az ideális fájdalomcsillapító hatásának új útjai. *Az orvostudomány aktuális problémái* 21:129-140, 1975
202. Magyar K., **Knoll J**: Para-substituted amphetamines and brain serotonin. *Pol. J. Pharmacol. Pharm.* 27:139-143, 1975
203. Friedmann T., Fürst Zs., Hársing L.G., **Knoll J**: Analgesic and antitussive effects of azidomorphine and azidocodeine derivatives. *Acta Physiol Acad Sci Hung* 48, 191-192, 1976
204. Hársing L.G., Friedmann T., **Knoll J**: Synergism of rymazolium and various antitussive agents. *Acta Physiol Acad Sci Hung* 48, 203, 1976
205. Illés P., Rónai A., **Knoll J**: Inhibition of neuromuscular transmission by prostaglandin E₁ in the circular muscle of the guinea pig vas deferens. *Med Biol* 54, 400-405, 1976
206. Kecskeméti V., Kelemen K., **Knoll J**: Dose-dependent effect of prostaglandins (PGE₁, PGE₂, PGF₂) on the cardiac transmembrane potential. *Acta Biol et Med Germanica* 35:1173-1174, 1976
207. **Knoll J**: History and highlights of pharmacology in Hungary. *Ann Rev Pharmacol Toxicol* 16:487-502, 1976

208. **Knoll J.**: Neural peptide (enkephalin) receptors in the ear artery of the rabbit. *European Journal of Pharmacology* 39:403-407, 1976
209. **Knoll J.**: Azidomorphines. Proc of the 6th Int Congress of Pharmacology, Drug Therapy Vol 4, Oxford New York, pp 31-45, 1976
210. **Knoll J.**, Hársing L.G.Jr., Friedmann T.: A 3-éter-6-azidomorfinok farmakológiája. Az azidoetilmorfin egy új köhögéscsillapító szelektálása. *Orvostudomány* 27, 263-284, 1976
211. Makleit S., **Knoll J.**, Bognár R., Berényi S., Kiss G.: Tozil-, ill. metil-származékok vizsgálata a morfinsorban. XVII. Azidomorfin származékok. I. *Magyar Kémiai Folyóirat* 82:430-431, 1976
212. Makleit S., **Knoll J.**, Bognár R., Berényi S., Somogyi G., Kiss G.: Tozil-, és metil-származékok vizsgálata a morfinsorban. XVIII. Azidomorfin származékok. II. *Magyar Kémiai Folyóirat* 82:432-433, 1976
213. Vizi E.S., **Knoll J.**: The inhibitory effect of adenosine and related nucleotide on acetylcholine release. *Neuroscience* 1: 391-398, 1976
214. Vizi E.S., Földes F.F., Rich J., **Knoll J.**: The structure-action relationship and kinetics of some naltrexone derivatives. *Pharmacology* 14:76-85, 1976
215. Zséli J., Vizi E.S., **Knoll J.**: Az azidomorfin és a morfin intestinális hatásának in vitro tanulmányozása. *Kísérletes Orvostudomány* 28:202-212, 1976
216. Friedmann T., Hársing L.G., **Knoll J.**: The antitussive effect of azidomorphine and 14-hydroxyazidomorphine. In: Symposium on Analgesics (Eds.: Knoll J., Vizi E.S.), Akadémiai Kiadó, Budapest, pp 67-70, 1976
217. Fürst S., Vizi ES., **Knoll J.**: Azidomorphines and acetylcholin release. In: Symposium on Analgesics (Eds.: Knoll J., Vizi E.S.), Akadémiai Kiadó, Budapest, pp 103-122, 1976
218. Hadházy P., Magyar K., Vizi E.S., **Knoll J.**: Inhibitory effects of prostaglandin E₁ on responses of rabbit ear artery to nerve stimulation and on release of norepinephrine. In: Advances in prostaglandin and thromboxane research. (Eds.: Samuelson, Paoletti), Raven Press, New York, pp 368-375, 1976
219. Hársing L.G.Jr., Friedmann T., Magyar K., **Knoll J.**: The effect of acetylcholin release./ The effects of azidoethylmorphine and related substances on cough and respiration. In: Symposium on Analgesics (Eds.: Knoll J., Vizi E.S.), Akadémiai Kiadó, Budapest, pp 61-65, 1976
220. Illés P., **Knoll J.**: The mechanism of specific desensitization to PGEs in guinea pig ileum. In: Symposium on Prostaglandins. (Eds.: Kelemen K., Knoll J.), Akadémiai Kiadó, Budapest, pp 89-92, 1976

221. Kalász H., Nagy J., Magyar K., **Knoll J.**: Gel chromatography of catecholamines. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Knoll J., Magyar K.), Akadémiai Kiadó, Budapest, pp 91-94, 1976
222. Kecskeméti V., Kelemen K., **Knoll J.**: Dose-dependent effect of PGF₂ on the cardiac transmembrane potentials. In: Symposium on Prostaglandins. (Eds.: Kelemen K., Knoll J.), Akadémiai Kiadó, Budapest, pp 23-30, 1976
223. Kecskeméti V., Kelemen K., **Knoll J.**: Comparative effect of prostaglandins on the cardiac transmembrane potentials. In: Advances in prostaglandin and thromboxane research. (Eds.: Samuelson, Paoletti), Raven Press, New York, pp 2, 1976
224. Kelemen K., Kecskeméti V., Kovács A., Miskó R., **Knoll J.**: Comparative effects of prostaglandins and celluline-A on the isolated heart. In: Symposium on Prostaglandins. (Eds.: Kelemen K., Knoll J.), Akadémiai Kiadó, Budapest, pp 31-38, 1976
225. Knoll B., Tímár J., Jóna G., **Knoll J.**: Serotonin metabolism and learning. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Magyar K., Knoll J.), Akadémiai Kiadó, Budapest, pp 27-32, 1976
226. **Knoll J.**: Gyógyszertan (Tankönyv, negyedik átdolgozott kiadás) 1-2 kötet, Medicina Könyvkiadó, Budapest, p 1-1064, 1976 (Handbook of Pharmacology revised 4th edition)
227. **Knoll J.**: Azidomorphines and homopyrimidazols: a new approach to the ideal analgesic. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Magyar K., Knoll J.), Akadémiai Kiadó, Budapest, pp 3-18, 1976
228. **Knoll J.**: Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Monoamine oxidase and its inhibition. Ciba Foundation Symposium 39 (new series) (Eds.: Wolstenholme G.E.S., Knight J.), Elsevier, Excerpta Medica pp 135-161, 1976
229. **Knoll J.**: Heterogeneity of monoamine oxidase: phenylethylamine oxidase and serotonin oxidase. In: Neuron concept today. (Eds: Szentágothai J., Hámori J., Vizi E.S.), Akadémiai Kiadó, Budapest, pp 109-117, 1976
230. Magyar K, Hajnal L, **Knoll J.**: The effect of p-substituted amphetamines on neurochemical transmission. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Magyar K., Knoll J.), Akadémiai Kiadó, Budapest, pp 9-18, 1976, Second Congress of the Hungarian Pharmacological Society, Budapest, Hungary

231. Magyar K., Zsilla G., **Knoll J.**: Absorption, distribution, elimination and biotransformation of azidomorphines. In: Symposium on Analgesics (Eds.: Knoll J., Vizi E.S.), Akadémiai Kiadó, Budapest, pp 39-50, 1976
232. Nagy J., Kalász H., Lemberkovits É., **Knoll J.**: A combined method for separation of biogenic amine perfluoroacyl derivatives and related compounds. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Magyar K., Knoll J.), Akadémiai Kiadó, Budapest, pp 95-99, 1976, Second Congress of the Hungarian Pharmacological Society, Budapest, Hungary
233. Sátory É., Mészáros Z., Magyar K., **Knoll J.**: The monoamine oxidase inhibitory effect of new homopirimidazol derivatives. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Magyar K., Knoll J.), Akadémiai Kiadó, Budapest, pp 43-46, 1976, Second Congress of the Hungarian Pharmacological Society, Budapest, Hungary
234. Timár J., Knoll B., Jóna G., **Knoll J.**: Reduced learning in substantia nigra lesioned rats. In: Symposium on pharmacology of catecholaminergic and serotonergic mechanisms. (Eds.: Magyar K., Knoll J.), Akadémiai Kiadó, Budapest, pp 33-37, 1976, Second Congress of the Hungarian Pharmacological Society, Budapest, Hungary
235. Török T., Vizi E.S., Knoll J.: Calcium dependent depolarization by PGE₁ of taenia coli smooth muscle. In: Symposium on Prostaglandins. (Eds.: Kelemen K., Knoll J.), Akadémiai Kiadó, Budapest, pp 97-101, 1976, Second Congress of the Hungarian Pharmacological Society, Budapest, Hungary
236. Vizi E.S., Földes F.F., Hahn E.F., Fishman J., **Knoll J.**: Agonist-antagonist interaction studies with morphine, 6-azidomorphine and oximorphine derivatives. In: Symposium on Analgesics (Eds.: Knoll J., Vizi E.S.), Akadémiai Kiadó, Budapest, pp 85-96, 1976, Second Congress of the Hungarian Pharmacological Society, Budapest, Hungary
237. Füst Zs., Földes F.F., **Knoll J.**: The influence of naloxone on barbiturate anaesthesia and toxicity in the rat. *Life Sciences* 20, 921-926, 1977
238. Illés P., Magazanik L.G., **Knoll J.**: Effect of prostaglandins E₁ and F₂ a on neuromuscular transmission in the frog sartorius muscle. *Acta Physiol Hung* 49, 235-239, 1977
239. Jounela A.J., Mattila M.J., **Knoll J.**: Interaction of selective inhibitors of monoamine oxidase with pethidine in rabbits. *Biochem Pharmacol* 26, 806-808, 1977
240. **Knoll J.**: Two kinds of opiate receptors. *Pol J Pharmacol Pharm* 29, 165-175, 1977
241. **Knoll J.**: A mitokondriális monoaminooxidáz két fő típusa (MAO-A) és (MAO-B) és szelektív gátlóik. *Orvostudomány* 28, 240-258, 1977

242. **Knoll J.**: A hazai gyógyszerkutatás jövőjéről. Magyar Tudomány 4, 252-259, 1977
243. **Knoll J.**, Fürst S., Makleit S.: The pharmacology of N-substituted azidomorphines. Arch int Phyarmacodyn Ther 228, 268-292, 1977
244. **Knoll J.**, Hársing L.G., Friedmann T.: Azidoethylmorphine, a new potent non-narcotic oral antitussive. Acta Physiol Hung 50, 341-356, 1977
245. Magyar K., **Knoll J.**: Selective inhibition of the 'B-form' of monoamine oxidase. Pol J Pharmacol Pharm 29, 233-246, 1977
246. Magyar K., Tekes K., Zólyomi G., Szűts T., **Knoll J.**: A p-Brom-metilamfetamin (V-111) sorsa a szervezetben. Orvostudomány 28, 75-100, 1977
247. Magyar K., Tekes K., **Knoll J.**: A p-Brom-metilamfetamin (V-111) optikai izomérjeinek hatása a központi idegrendszer neurokémiai transzmissziójára. Orvostudomány 28, 265-280, 1977
248. Makleit S., **Knoll J.**, Bognár R., Berényi S., Somogyi G., Kiss G.: Conversions of tosyl and mesyl derivatives of the morphine group. XVIII. 'Azidomorphine' derivatives. I. Acta Chimica Acad Sci Hung 93, 165-168, 1977
249. Makleit S., **Knoll J.**, Bognár R., Berényi S., Somogyi G., Kiss G.: Conversions of tosyl and mesyl derivatives of the morphine group. XVIII. 'Azidomorphine' derivatives. II. Acta Chimica Acad Sci Hung 93, 169-174, 1977
250. Makleit S., **Knoll J.**, Bognár R., Berényi S., Somogyi G., Kiss G.: Conversions of tosyl and mesyl derivatives of the morphine group. XVIII. 'Azidomorphine' derivatives. III. Acta Chimica Acad Sci Hung 93, 175-181, 1977
251. Somogyi G.T., Vizi E.S., **Knoll J.**: Effect of hemicholinium-3 on the release and synthesis of acetylcholine in Auerbach's plexus guinea-pig ileum. Neuroscience 2, 791-796, 1977
252. Vizi E.S., Rónai A., Hársing L.G., **Knoll J.**: Inhibitory effect of dopamine on acetylcholine release from caudate nucleus. Pol J Pharmacol Pharm 29, 201-211, 1977
253. Vizi E.S. Hársing L.G., **Knoll J.**: Presynaptic inhibition leading to disinhibition of acetylcholine release from interneurons of the caudate nucleus: effects of dopamine, β -endorphin and D-Ala²-Pro³-enkephalinamide. Neuroscience 2, 953-961, 1977
254. Vizi E.S., Rónai A., Hársing L.G., **Knoll J.**: Presynaptic modulation by norepinephrine and dopamine of acetylcholine release in the peripheral and central nervous system. In: Cholinergic Mechanisms and Psychopharmacology. (Ed.: Jenden D.J.), Plenum Publ Corp, pp 587-603, 1977

255. Hársing L.G.Jr., Vizi E.S., **Knoll J.**: Increase by enkephalin of acetylcholine release from striatal slices of the rat. *Pol J Pharmacol Pharm* 30, 387-395, 1978
256. Kecskeméti V., Kelemen K., **Knoll J.**: Effect of verapamil and D 600 on cardiac transmembrane potential. *Acta Physiol Hung* 51, 55-59, 1978
257. Kecskeméti V., Kelemen K., **Knoll J.**: Comparative effects of PGF₂ and PGA₁ on the cardiac transmembrane potentials. *Acta Biol Med Germ* 37, 821-824, 1978
258. Knoll B., Vizi ES., Held Gy., **Knoll J.**: The effect of p-Bromo-methamphetamine (V-111) on the flexor reflex of spinal rat. *Pol J Pharmacol Pharm* 30, 225-231, 1978
259. **Knoll J.**: Selective inhibition of noradrenergic transmission in vascular smooth muscle. *Pol J Pharmacol Pharm* 30, 269-280, 1978
260. **Knoll J.**: On the dual nature monoamine oxidase. *Horizons in Biochem Biophys* 5, 37-64, 1978
261. **Knoll J.**: The possible mechanism of action of (-)deprenyl in Parkinson's disease. *J Neural Transm* 43, 177-198, 1978
262. **Knoll J.**: Azidomorfínek és homopirimidazolok: új próbálkozás az ideális fájdalomcsillapító megközelítésére. *Orvosi Hetilap* 119, 1203-1211, 1978
263. **Knoll J.**: Opiát receptorok két típusának (A és B receptorok) megkülönböztetése N-szubsztituált azidomorfínek segítségével. *Orvostudomány* 29, 131-154, 1978
264. **Knoll J.**: Hatás és vegyi szerkezet összefüggése szelektív monoaminooxidáz bénítók esetében. *Kémiai Közlemények* 50, 57-71, 1978
265. **Knoll J.**: A (-)deprenil valószínű hatásmódjáról Parkinson kórban. *Orvostudomány* 29. 261-276, 1978
266. **Knoll J.**, Illés P.: The isolated nictitating membrane of the cat. A new model for the study of narcotic analgesics. *Pharmacology* 17, 215-220, 1978
267. **Knoll J.**, Illés P., Medzihradzky K.: The action of enkephalins and enkephalin analogues on neurotransmission in the isolated nictitating membrane of the cat. *J Pharm Pharmacol* 30, 394-395, 1978
268. **Knoll J.**, Ecsery Z., Magyar K., Satory É.: Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. *Biochem Pharmacol* 27, 1739-1747, 1978
269. Magyar K., Lengyel M., **Knoll J.**: Absorption, distribution and elimination of drotaverine. *Acta Physiol Hung* 51, 401-411, 1978

270. **Knoll J.**: The pharmacology of selective irreversible monoamine oxidase inhibitors. In: Enzyme-activated irreversible inhibitors. (Eds.: Seiler N., Jung M.J., Koch-Weser J.), Elsevier/North Holland Biomedical Press, pp 253-269, 1978.
271. Ekstedt B., Magyar K., **Knoll J.**: Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? *Biochem Pharmacol* 28, 929-923, 1979
272. Hársing L.G. Jr., Magyar K., Tekes K., Vizi E.S., **Knoll J.**: Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. *Pol J Pharmacol Pharm* 31, 297-307, 1979
273. Hársing L.G. Jr., Illés P., Fürst Zs., Vizi E.S., **Knoll J.**: The effect of prostaglandin E₁ on acetylcholine release from the cat brain. *Acta Physiol Hung* 54, 177-185, 1979
274. Hársing L.G. Jr., **Knoll J.**, Vizi E.S.: Regulation of neurochemical transmission in the extrapyramidal system. *Acta Physiol Acad Sci Hung* 53, 175, 1979
275. **Knoll J.**: (-)Deprenyl – the MAO inhibitor without the 'cheese effect'. *TINS* 1, 111-113, 1979
276. **Knoll J.**: Azidomorphines: a new family of potent analgesics with low dependence capacity. *Prog Neuro-Psychopharmacol* 3, 95-108, 1979
277. **Knoll J.**: Satietin: a highly potent anorexogenic substance in human serum. *Physiol Behav* 23, 497-502, 1979
278. **Knoll J.**: Issekutz Béla (1886-1979). *Orvosi Hetilap* 120, 2714- 2715, 1979
279. **Knoll J.**, Gyires K., Mészáros Z.: 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4H-pyrido(1,2a)pyrimidine-3-carboxamide (Chinoin-127), a potent non-narcotic analgesic and antiinflammatory agent. *Arzneim-Forsch* 29, 766-773, 1979
280. **Knoll J.**: Satietin: a highly potent anorexogenic substance in human serum. *Neurosci Letts Suppl* 3, 194, 1979
281. Timar J., Knoll B., Gyarmati Zs., **Knoll J.**: Effect of selective monoamine oxidase (MAO) inhibitors on conditioned avoidance responses (CAR) of rats. *Pol J Pharmacol Pharm* 31, 251-260, 1979
282. Kecskeméti V., Kelemen K., **Knoll J.**: Comparative effect of primary prostaglandins and prostacyclin on cardiac transmembrane potentials. 3rd Congr of the Hung Pharmacol Soc, Budapest, Hungary, Abstracts, p 44, 1979
283. Knoll B., Timar J., **Knoll J.**: The type of MAO in the nigrostriatal dopaminergic neurons of the rat. In: *Catecholamines: Basic and Clinical Frontiers*.

(Eds.:Usdin E., Kopin I.J., Barchas J.), Pergamon Press, New York, Vol. II., pp 1768-1770, 1979

284. **Knoll J.**: Structure-activity relationships of the selective inhibitors of MAO-B. In: Monoamine-oxidase: Structure, Function and Altered Function (Eds.: Singer T.P., Von Korff R.W., Murphy D.L.), Academic Press, New York, pp 431-446, 1979

285. **Knoll J.**: Angiohypotensin: a selective endogenous inhibitor of neuromuscular transmission in vascular smooth muscle. In: Catecholamines: Basic and Clinical Frontiers. (Eds.:Usdin E., Kopin I.J., Barchas J.), Pergamon Press, New York, Vol. II., pp 1152-1154, 1979

286. **Knoll J.**: Studies on the central effects of (-)cathinone. Natl Inst Drug Abuse Res Monogr Ser 27, 322-323, 1979

287. Knoll B., Timar J., Gyarmati Zs., Held Gy., **Knoll J.**: A és B típusú monoamino oxidáz enzimbénítók hatása patkányok viselkedési mintáira. I. Orvostudomány 30-31, 459-467, 1979-1980.

288. Knoll B., **Knoll J.**: Studies with satietin, a potent anorexogenic peptide isolated from human serum. Proc IUPS 14, 517, 1980

289. **Knoll J.**: Szatietin: a táplálékfelvételt szelektíven gátló anyag az emberi vérben. Orvostudomány 30-31, 351-383, 1979-1980

290. **Knoll J.**: Issekutz Béla (1886-1979). Orvostudomány 30-31, 11-15, 1979-1980

291. **Knoll J.**: The anorexogenic effect of satietin in comparison to the effects of calcitonin, cholecystokinin and pGlu-His-GlyOH. Neurosci Letters Suppl., 5, 317, 1980

292. Magyar K., Hársing L.G., Tekes K., **Knoll J.**: The role of metabolic factors in the interaction between opiates and homopyrimidazols in the central nervous system. Arch Toxicol Suppl., 4, 376-379, 1980

293. Timar J., Knoll B., Gyarmati Zs., Held J., **Knoll J.**: A és B típusú monoamino oxidáz enzimbénítók hatása patkányok viselkedési mintáira. II. Orvostudomány 30-31, 469-479, 1979-1980

294. Friedmann T., **Knoll J.**: The effects of azidomorphines on the opiate receptor(s) of guinea pig ileum. In: Opiate receptors and the neurochemical correlates of pain. (Eds.: Knoll J., Fürst S.), Akadémiai Kiadó, Pergamon Press, Budapest, pp 45-52), 1980.

295. Gyires K., **Knoll J.**: Comparison of the analgesic action of inhibitors of PG synthesis, Chinoin-127 and morphine. In: Opiate Receptors and the Neurochemical Correlates of Pain. (Eds.: Knoll J., Fürst S.), Akadémiai Kiadó, Pergamon Press, Budapest, pp 227-233), 1980.

296. Hársing L.G, Vizi E.S., **Knoll J.**: Sensitivity of opiate receptors in withdrawal syndrome. In: Aminergic and Peptidergic Receptors. (Eds.: Vizi E.S., Wollemann M.), Akadémiai Kiadó-Pergamon Press, Budapest, pp 95-113, 1980.
297. Hársing L.G.Jr., Magyar K., Tekes K., Vizi E.S., **Knoll J.**: Deprenyl inhibits dopamine uptake in the rat striatum in vivo. In: Monoamine oxidases and their selective inhibition. (Eds.: Knoll J., Magyar K.), Akadémiai Kiadó-Pergamon Press, Budapest, pp 45-56, 1980.
298. Kecskeméti V., Kelemen K., **Knoll J.**: Effect of primary prostaglandins and prostacyclin on cardiac transmembrane potentials. In: Prostanoids (Eds.: Knoll J., Kecskeméti V.), Akadémiai Kiadó-Pergamon Press, Budapest, pp 81-88, 1980.
299. Kelemen K., Markó R., Kecskeméti V., **Knoll J.**: Comparative effect of prostacyclin on primary prostaglandins on cardiac transmembrane currents. In: Prostanoids (Eds.: Knoll J., Kecskeméti V.), Akadémiai Kiadó-Pergamon Press, Budapest, pp 89-93, 1980.
300. Kerecsen L., **Knoll J.**: A new model for the study of opiate B receptors: isolated splenic strip of the cat. In: Opiate Receptors and the Neurochemical Correlates of Pain. (Eds.: Knoll J., Fürst S.), Akadémiai Kiadó, Pergamon Press, Budapest, pp 29-32), 1980.
301. **Knoll J.**: Monoamine oxidase inhibitors: chemistry and pharmacology. In: Enzyme Inhibitors as Drugs. (Ed.: Sandler M.), McMillan Press Ltd., London, pp 151-171, 1980
302. **Knoll J.**: Selective inhibitors of MAO-B with different pharmacological profiles. In: Monoamine oxidase and their selective inhibition. (Eds.: Knoll J., Magyar K.), Akadémiai Kiadó-Pergamon Press, Budapest, pp 23-36, 1980.
303. **Knoll J.**: Highly selective peptide-chalones in human serum. A concept on the control of physiological functions by blood-borne selective inhibitors of neurochemical transmission. In: Modulation of Neurochemical Transmission (Eds.: Knoll J., Vizi ES.) Akadémiai Kiadó- Pergamon Press, Budapest, pp 97-125, 1980.
304. **Knoll J.**: Opiate receptors relate to cholinergic and opiate-B receptors to catecholaminergic neurons. In: Opiate Receptors and the Neurochemical Correlates of Pain. (Eds.: Knoll J., Fürst S.), Akadémiai Kiadó, Pergamon Press, Budapest, pp 3-13), 1980.
305. Magyar K., Ecseri Z., Bernáth G., Satory E., **Knoll J.**: Structure-activity relationship of selective inhibitors of MAO-B. In: Monoamine Oxidases and their Selective Inhibition. (Eds.: Knoll J., Magyar K.), Akadémiai Kiadó-Pergamon Press, Budapest, pp 11-21, 1980.
306. Tekes K., Hársing L.G. Jr., Magyar K., **Knoll J.**: The role of metabolic factors in the interaction between opiates and homopyrimidazols in the central nervous system. In: Opiate Receptors and the Neurochemical Correlates of Pain. (Eds.:

Knoll J., Fürst S.), Akadémiai Kiadó, Pergamon Press, Budapest, pp 201-205), 1980.

307. Zsilla G., Knoll B., **Knoll J.**: Effect of p-bromo-metamphethamine (V-111) on serotonergic and catecholaminergic mechanisms. In: Synaptic Constituents in Health and Disease. (Eds.: Brzin M., Sket D., Bachelard H.), Pergamon Press, New York, pp 462, 1980

308. Kerecsen L., **Knoll J.**: A new model for the study of opiate-B receptors: isolated splenic strip of the cat. *Pharmacology* 22, 8-14, 1981

309. **Knoll J.**: A dependenciákhoz vezető szerek farmakológiai jellemzői. *Alkohológia* 3, 129-133, 1981

310. **Knoll J.**: Béla Issekutz (1886-1979). *Acta Physiol Hung* 4, 313-315, 19

311. **Knoll J.**, Kerecsen L., Somogyi G.T., Kovács A.: Opiate agonists inhibit noradrenaline release via opiate-B receptors and N-cyclopropylmethylnorazidomorphine (CAM) blocks electrically evoked contractions via histamine in the mouse vas deferens. *Arch Int Pharmacodyn Ther* 251, 52-65, 1981

312. Magyar K., Tekes K., Zólyomi G., Szüts T., **Knoll J.**: The fate of p-bromo-methylamphetamine (V-111) in the body. *Acta Physiol Hung* 57, 285-307, 1981

313. Török T., Vizi E.Sz., Magyar K., **Knoll J.**: Az elektrogén Na⁺-pumpa szerepe az adrenalin elektrofiziológiai hatásaiban tengerimalac taenia coli simaizmon. *Orvostudomány* 32, 33-48, 1981

314. Yen T.T., Dalló J., **Knoll J.**: Szelektív monoaminooxidáz bénítók afrodisziás hatása hím patkányokon. *Kísérletes Orvostudomány* 33, 484-488, 1981

315. Zsilla G., Knoll B., **Knoll J.**: The action of single and repeated doses of p-bromo-methamphetamine on monoamine content and turnover rate in rat brain.

316. **Knoll J.**: Further experimental support to the concept that (-)deprenyl facilitates dopaminergic neurotransmission in the brain. In: Monoamine Oxidase: Basic and Clinical Frontiers. (Eds.: Kamyó K., Usdin E., Nagatsu T.), Elsevier, Amsterdam, pp 230-240, 1981

317. **Knoll J.**: Can the suicide inactivation of MAO by deprenyl explain its pharmacological effects? In: Molecular Basis of Drug Action. (Eds.: Singer T., Ondarza N.), Elsevier, Amsterdam, pp 185-201, 1981

318. **Knoll J.**: The pharmacology of selective MAO inhibitors. In: Monoamine Oxidase Inhibitors. The State of the Art. (Eds.: Youdim M.B.H., Paykel E.S.), Wiley, New York, pp 45-61, 1981

319. Friedmann T., Medzihradzky K., Kovács A., Kerecsen L., Szécsi J.H., Di Gleria K., **Knoll J.**: Comparison of biological activities of enkephalin analogues in

isolated organs. Pol J Pharmacol Pharm 34, 53-61, 1982

320. Fürst S., **Knoll J.**: Quantitative studies of the antagonism by naloxone and N-cyclopropylmethylnorazido-dihydro-isomorphine (CAM) of different opiates. Pol J Pharmacol Pharm 34, 1-3, 1982

321. Fürst Zs., **Knoll J.**: Naloxon és N-cyclopropylmethyl-norazidodihidroizomorfin (CAM) antagonista hatásának kvantitatív vizsgálata. Orvostudomány 33, 51-62, 1982

322. Fürst S., Friedmann T., Bartolini A., Bartolini R., Aiello-Malmberg P., Galli A., Somogyi G.T., **Knoll J.**: Direct evidence that eseroline possesses morphine like effects. Eur J Pharmacol 83, 233-243, 1982

323. Gyarmati Zs., Földes J., Korányi L., Knoll B., **Knoll J.**: A szatietin hatása a szénhidrát anyagcserére. Orvostudomány 33, 547-551, 1982

324. Knoll B., **Knoll J.**: The selectivity of the anorectic effect of satietin. I. The ineffectiveness of satietin on behavioral tests. Pol J Pharmacol Pharm 34, 17-23, 1982

325. **Knoll J.**: Satietin: a centrally acting potent anorectic substance with a long-lasting effect in human and mammalian blood. Pol J Pharmacol Pharm 34, 3-16, 1982

326. Deprenyl in Parkinson's disease. The Lancet, Editorial, Sept, 25, 695-696, 1982

327. **Knoll J.**: A monoamino-oxidáz két típusának szelektív gátlói és terápiás felhasználásuk új lehetőségei. Orvosi Hetilap 123, 1335-1344, 1982

328. **Knoll J.**, Dalló J., Yen T.T.: A (-)deprenyl tartós afrodisziás hatása szexuálisan „lusta” öreg hím patkányokon. Orvostudomány 33, 179-194, 1982

329. **Knoll J.**, Magyar K.: Some puzzling pharmacological effects of monoamine oxidase inhibitors. (Adv Biochem Psychopharmacol 5, 393-408, 1972)

This Week's Citation Classic January 15, 1982

330. Nagy J., Kalász H., **Knoll J.**: An improved method for the preparation of highly purified satietin samples from human serum. Pol J Pharmacol Pharm 34, 47-52, 1982

331. Nagy J., Kalász H., **Knoll J.**: Szetietin: a táplálkozást szelektíven szabályozó endogén anyag. Izolálás és kémiai jellemzés. Orvostudomány 33, 71-84, 1982

332. Sándor G., **Knoll J.**: A szatietin szelektív anorexiás hatása. A szatietin hatástalansága éhező patkányok vízfelvételére, valamint a „kondicionált averzió” paradigmában. Orvostudomány 33, 92-98, 1982

333. Sándor G., **Knoll J.**: The selectivity of the anorectic effect of satietin. II. Ineffectiveness of satietin on the water intake in food deprived rats. Effect of satietin in 'conditioned aversion' paradigm. *Pol J Pharmacol Pharm* 34, 25-32, 1982
334. Szirtes T., Knoll B., Kisfaludy L., **Knoll J.**: Étvágycsökkentő hatású tripeptidek. *Orvostudomány* 33, 63-70, 1982
335. Timár J., **Knoll J.**: The selectivity of the anorectic effect of satietin: III. The ineffectiveness of satietin on metabolic rate, body temperature and blood pressure. *Pol J Pharmacol Pharm* 34, 33-39, 1982
336. Yen T.T., Dalló J., **Knoll J.**: The selectivity of the anorectic effect of satietin on the sexual performance of male CFY rats. *Pol J Pharmacol Pharm* 34, 41-45, 1982
337. Yen T.T., Dalló J., **Knoll J.**: The aphrodisiac effect of low doses of (-)deprenyl in male rats. *Pol J Pharmacol Pharm* 34, 303-308, 1982
338. Yen T.T., Dalló J., **Knoll J.**: A szatietin szelektív anorexiás hatása. A szatietin hatásának vizsgálata hím patkányok szexuális viselkedésére. *Orvostudomány* 33, 85-89, 1982
339. Kecskeméti V., Kelemen K., Markó R., **Knoll J.**: Drugs affecting the calcium dependent slow depolarization mechanism of the cardiac cell membrane. In: *Advances in Myocardiology Vol. 3.*, (Eds.: Chazov E., Smirnov V., Ohalla N.S.), Plenum Publish, New York, pp 205-214, 1982
340. Kecskeméti V., Solti F., Szabó Z., **Knoll J.**: Analysis of the transmembrane action potentials of the human atrial fibers. In: *Electrocardiology 81'*, (Eds.: Antalóczy Z., Préda J.), Akadémiai Kiadó, Budapest, pp 31-35, 1982
341. Kelemen K., Kecskeméti V., Markó R., **Knoll J.**: Drugs affecting the tetrodotoxin sensitive 'fast' sodium mechanism in the cardiac cell membrane. In: *Advances in Myocardiology Vol. 3.*, (Eds.: Chazov E., Smirnov V., Ohalla N.S.), Plenum Publish, New York, pp 115-124, 1982
342. **Knoll J.**: Anorectic agents and satietin, an endogenous inhibitor of food intake. In: *Advances in Pharmacology and Therapeutics II, Vol. 1, CNS Pharmacology Neuropeptides*, (Eds.: Yoshida H., Hagihara Y., Ebashi S.), Pergamon Press, Oxford, pp 147-192, 1982
343. **Knoll J.**: Satietin: endogenous regulation of food intake. In: *Regulatory Peptides: From Molecular Biology to Function*. (Eds.: Costa E., Trabucchi M.), Raven Press, New York, pp 501-509, 1982
344. **Knoll J.**: Selective inhibition of B type monoamine oxidase in the brain: a drug strategy to improve the quality of life in senescence. In: *Strategy in Drug Research*, (Ed.: Keverling Buisman J.A.), Elsevier, Amsterdam, pp 107-135, 1982
345. Nagy J., **Knoll J.**, Kenney W.C., Singer T.P.: Separation and characterization of flavin derivatives by means of gel chromatography and high performance thin-

layer chromatography. In: Flavins and Flavoproteins, (Eds.: Massey V., Williams C.H.Jr.), Elsevier, New York, pp 571-578, 1982

346. Zsilla G., **Knoll J.**: The action of (-)deprenyl on monoamine turnover rate in rat brain. In: Typical and Atypical Antidepressants: Molecular Mechanisms, (Eds.: Costa E., Racagni G.), Raven Press, New York, pp 211-217, 1982

347. Birkmayer W., **Knoll J.**, Riederer P., Youdim M.B.H.: (-)Deprenyl leads to prolongation of l-dopa efficacy in Parkinson's disease. *Mod Probl Pharmacopsychiat* 19, 170-176, 1983

348. **Knoll J.**: Deprenyl (selegiline). The history of its development and pharmacological action. *Acta Neurol Scand Suppl* 95, 57-80, 1983

349. **Knoll J.**, Yen T.T., Dalló J.: Long-lasting, true aphrodisiac effect of (-)deprenyl in sexually sluggish old male rats. *Mod Probl Pharmacopsychiat* 19, 135-153, 1983

350. Zsilla G., Barbaccia M.L., Gandolfi O., **Knoll J.**, Costa E.: (-)Deprenyl a selective MAO-B inhibitor increases ³H-imipramine binding and decreases beta-adrenergic receptor function. *Eur J Pharmacol* 89, 111-117, 1983

351. Kalász H., Nagy J., **Knoll J.**: Scouting on thin-layer plates for optimal displacement chromatography of phenylalkylamines. In: *Chromatography and Mass Spectrometry in Biomedical Sciences* (Ed.: Frigerio A.), Elsevier, Amsterdam, pp 203-214, 1983.

352. **Knoll J.**: Introductory remarks. In: *Chromatography: the State of the Art.* (Eds.: Kalász H., Ettre L.S.), Akadémiai Kiadó, Budapest, pp 1-7, 1983.

353. **Knoll J.**: Gyógyszertan (Tankönyv, ötödik, átdolgozott kiadás) 1-2 kötet), Medicina Könyvkiadó, Budapest, pp-1-1128, 1983 (Handbook of Pharmacology, revised 5th edition)

354. Nagy J., Kalász H., **Knoll J.**: Isolation and characterization of a highly selective anorexogenic substance by chromatography and electrophoresis. In: *Chromatography and Mass Spectrometry in Biomedical Sciences* (Ed.: Frigerio A.), Elsevier, Amsterdam, pp 421-432, 1983.

355. Birkmayer W., Riederer P., Linauer W., **Knoll J.**: (-)Deprenyl plus phenylalanine in the treatment of depression. *J Neural Transm* 59, 81-87, 1984.

356. **Knoll J.**: Endogenous anorexic substances. *Clin Neuropharmacol* 7, Suppl.1., 390-391, 1984.

357. **Knoll J.**: Satietin, a 50 000 dalton glycoprotein in human serum with potent, long-lasting and selective anorectic activity. *J Neural Transm* 59, 163-194, 1984.

358. **Knoll J.**: Satielin, a blood-borne anorectic glycoprotein, as the putative rate-limiting satiety signal in the negative feedback of food-intake. *Z. Ernährungswiss* 23, 85-103, 1984.
359. Nagy J., Várady L., Kalász H., **Knoll J.**: Molecular weight measurement of human satietin. *J. Chromatogr.* 317, 165-172, 1984.
360. Zsilla G., Held Gy., Székely A.M., **Knoll J.**, Barbaccia M.L., Cheney D.L., Gandolfi O., Costa E: Modification of synaptic receptor function by (-)deprenyl. *Clin Neuropharmacol* 7, Suppl.1., 312-313, 1984.
361. Kerecsen L., Kalász H., **Knoll J.**: The effect of (-)deprenyl on striatal dopamine release in the rat. In: *Regulation of Transmitter Function: Basic and Clinical Aspects.* (Eds.: Vizi E.S., Magyar K.), Akadémiai Kiadó, Budapest, pp 349-352, 1984.
362. **Knoll J.**: Satielin: a blood-borne, highly selective and potent anorectic glycoprotein. In: *Biomedical Significance of peptide research,* (Eds.: László F.A., Antoni F.), Akadémiai Kiadó, Budapest, pp 103-114, 1984.
363. **Knoll J.**: Anorectic agents and endogenous anorectic substances. In: *Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics,* (Eds.: Lemberger L., Reidenber M.M.), Am Soc for Pharm Exp Ther, Bethesda, pp 103-127, 1984.
364. Székely A.M., Zsilla G., Held Gy., **Knoll J.**: Differences by repeated doses of (-)deprenyl on monoamine receptor density in rat brain. In: *Regulation of Transmitter Function: Basic and Clinical Aspects.* (Eds.: Vizi E.S., Magyar K.), Akadémiai Kiadó, Budapest, pp 321, 1984.
365. Szökő É., Kalász H., **Knoll J.**, Fonyó M., Magyar K.: Serum binding of (-)deprenyl. In: *Regulation of Transmitter Function: Basic and Clinical Aspects.* (Eds.: Vizi E.S., Magyar K.), Akadémiai Kiadó, Budapest, pp 353-356, 1984.
366. Zsilla G., Székely A.M., Held Gy, Cheney D.L., Gandolfi O., **Knoll J.**: Neurochemical evidence for facilitation of dopaminergic function in rat brain by repeated doses of (-)deprenyl. In: *Regulation of Transmitter Function: Basic and Clinical Aspects.* (Eds.: Vizi E.S., Magyar K.), Akadémiai Kiadó, Budapest, pp 345-348, 1984.
367. Birkmayer W., **Knoll J.**, Riederer P., Youdim M.B.H., Hárs V., Márton J.: Increased life expectancy resulting from addition of L-deprenyl to Madopar^R treatment in Parkinson's disease: a longterm study. *J Neural Transm* 64, 113-127, 1985.
368. Fürst S., **Knoll J.**: Differentiation of multiple analgesic opiate receptors. *Int J Tiss Reac* 8, 69-77, 1985.

369. Gyarmati S., Földes J., Korányi L., Knoll B., **Knoll J.**: The anorectic effect of satietin is unrelated to carbohydrate metabolism. *Physiol Behav* 34, 167-170, 1985.
370. Gyires K., **Knoll J.**: Inhibitory effect of some pyrido-pyrimidine derivatives on gastric mucosal necrosis induced by alcohol, HCl, NaOH and hypertonic NaCl in rats. *Digestion* 31, 169-170, 1985.
371. Gyires K., **Knoll J.**: Some further data about the inhibitory action of pyrido-pyrimidines on mucosal damage. *Digest Dis Sci* 30, 378, 1985.
372. Gyires K., Fürst S., Miklya I., Budavári I., **Knoll J.**: Analysis of analgesic and antiinflammatory effect of rimazolium- a pyrido-pyrimidine derivative- compared with that of PG synthesis inhibitors. *Drugs Exp Clin Res* 11, 493-500, 1985
373. **Knoll J.**: The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence. *Mech Ageing Dev* 30, 109-122, 1985.
374. **Knoll J.**: Satietin, a blood-borne, highly selective and potent anorectic glycoprotein. *Biomed Biochim Acta* 44, 317-328, 1985.
375. Korbonits D., Szejtli J., Szőke A., Antus S., Gottsegen A., Nógrádi M., Fürst S., **Knoll J.**: Cannabinoids with an other side chain. Synthesis, solubilization and analgesic properties. *Eur J Med Chem Ther* 20, 492-494, 1985
376. Sándor G., **Knoll J.**: The time-structure of the anorectic effect of satietin. *Physiol Behav* 34, 851-853, 1985.
377. **Knoll J.**: Satietin, a potent and selective endogenous anorectic glycoprotein. In: *Psychopharmacology and Food*. (Eds.: Sandler M., Silverstone T.) Oxford University Press, Oxford, pp: 110-129, 1985.
378. Kerecsen L., Kalász H., Tarcali J., Fekete J., **Knoll J.**: Measurements of DA and DOPAC release from rat striatal slice preparations 'in vitro' using HPLC with electrochemical detection. In: *Chromatography, the State of the Art*, (Eds.: Kalász H., Ettre L.S.), Akadémiai Kiadó, Budapest, pp:195-202, 1985.
379. Knoll B., Timár J., **Knoll J.**: The selectivity of the anorectic effect of satietin-D. In: *Advances in Pharmacological Research and Practice, Endogenous Anorectics*, (Eds.: Knoll B., Nagy J., Timár J.) Pergamon Press, Akadémiai Kiadó, 309-315, 1985.
380. **Knoll J.**: Satietin, a blood-borne glycoprotein in regulation of food intake. In: *Endocoids*, (Eds.: Lal H., Labella F., Lane J.), Alan R. Liss Inc., New York, pp: 515-522, 1985.
381. Nagy J., Mazsaroff I., Várady L., **Knoll J.**: Studies on the purification and properties of satietin, an anorexigenic glycoprotein of biological origin. In: *Chromatography the State of Art* (Eds.: Kalász H., Ettre L.S.), Akadémiai Kiadó, Budapest, pp: 337-358, 1985.

382. Dalló J., Lekka N., **Knoll J.**: The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine. *Pol. J. Pharmacol. Pharm.* 38, 251-255, 1986.
383. Kalász H., Kerecsen L., Hollósi I., Magyar K., **Knoll J.**: Oxidative dealkylation of (-)deprenyl following hydrogen peroxide treatment under 'in vitro' circumstances. *Acta Physiol. Hung.* 68, 318-325, 1986.
384. Knoll B., Timár J., **Knoll J.**: The selectivity of the anorectic effect of satietin-D. *Neurosci. Letts., Suppl.*, 26, S-245, 1986.
385. **Knoll J.**: Medikamentöse Strategie zur Verbesserung der Lebensqualität in der Seneszenz. *Wiener Med. Wochens* 136, Suppl., 3-18, 1986.
386. **Knoll J.**: Satietin, a blood-borne glycoprotein in regulation of food intake. In: *Endocoids*, (Eds.: Lal H., Labella F., Lane J.), Alan R. Liss Inc., New York, pp: 515-522, 1985.
387. **Knoll J.**: Striatal dopamine, aging and (-)deprenyl. *Jugoslav Physiol Pharmacol Acta* 22, 261-273. 1986.
388. **Knoll J.**: (-)Deperenyl, inhibitore selettivo della monoamino-ossidasi di tipo B nella terapia del morbo di Parkinson. *Rassegna* 52, 184-187, 1986.
389. **Knoll J.**: The pharmacology of (-)deprenyl. *J. Neural Transm Suppl.*, 22, 75-89, 1986.
390. **Knoll J.**: Critical role of MAO inhibition in Parkinson's disease. *Advances in Neurology* 45, 107-110, 1986.
391. Knoll J.: Megemlékezés Issekutz Béla születésének 100. évfordulójáról. *Orvosi Hetilap* 127 (24): 1463-1466, 1986
392. Timár J., Knoll B., **Knoll J.**: Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged. *Arch. Int. Pharmacodyn. Ther.* 284, 255-266, 1986.
393. Timár J., Knoll B., **Knoll J.**: The effect of (-)deprenyl on amphetamine-stereotypy. *Neurosci Letts Suppl.*, 26, S-518, 1986.
394. Zsilla G., Földi P., Held Gy., Székely A.M., **Knoll J.**: The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. *Pol J Pharmacol Pharm* 38, 57-67, 1986.
395. Zsilla G., Székely A.M., **Knoll J.**: The imipramine recognition sites are upregulated and 5HT uptake is unchanged after three week injections of (-)deprenyl. *Neurosci Letts Suppl.*, 26, S-107, 1986.

396. Dalló J., Lekka N., **Knoll J.**: Age dependent decrease of copulatory activity and its correction by (-)deprenyl in male rats. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Klemen K.) Vol.3, Sect. 5., Pergamon Press, Akadémiai Kiadó, Budapest, pp 35-38, 1986.
397. Friedmann T., **Knoll J.**: Relationship between the suggested opioid receptors. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.3., Pergamon Press, Akadémiai Kiadó, Budapest, pp 255-264, 1986.
398. Fürst S., **Knoll J.**: Characteristics of opiate A and B receptors stimulated or inhibited by intrathecally administered opiates. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.3., Pergamon Press, Akadémiai Kiadó, Budapest, pp 221-230, 1986.
399. Gyires K., Hermecz I., **Knoll J.**: Comparison of the analgesic action of inhibitors of PG synthesis, Ch-127 and morphine. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.7., Pergamon Press, Akadémiai Kiadó, Budapest, pp 473-479, 1986.
400. Harmath S., Barna I., **Knoll J.**: Isolation of satietin-D by immunoabsorbent chromatography and the immunochemical detection of satietins in human plasma. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.6., Pergamon Press, Akadémiai Kiadó, Budapest, pp 293-300, 1986.
401. Kerecsen L., Kalász H., **Knoll J.**: (-)deprenyl enhances dopamine release from isolated striatal preparations of the rat following chronic pretreatment. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.5., Pergamon Press, Akadémiai Kiadó, Budapest, pp 27-33, 1986.
402. Knoll B., Timár J., **Knoll J.**: The selectivity of the anorectic effect of satietin-D. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.6., Pergamon Press, Akadémiai Kiadó, Budapest, pp 309-315, 1986.
403. **Knoll J.**: Striatal dopamine, aging and deprenyl. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.5., Pergamon Press, Akadémiai Kiadó, Budapest, pp 7-26, 1986.
404. **Knoll J.**: Satietyins: a family of highly potent and selective anorectic glycoproteins in human and mammalian blood. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.6., Pergamon Press, Akadémiai Kiadó, Budapest, pp 233-269, 1986.

405. **Knoll J.**: Role of B-type monomine oxidase inhibition in the treatment of Parkinson's disease. An update. In: Movement Disorders. (Eds.: Shah N.S., Donald A.G.), Plenum Press, New York, pp 53-81, 1986.
406. Mazsaroff I., Várady L., Nagy J., **Knoll J.**: Subsequent analysis to proteolytic digestion of satietin-D. In: Chromatography '84'. (Eds.: Kalász H., Ettre L.S.), Akadémiai Kiadó, Budapest, pp 527-532, 1986.
407. Nagy J., Mészáros M., Czizér E., **Knoll J.**: Isolation and chemical analysis of human satietins. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.6., Pergamon Press, Akadémiai Kiadó, Budapest, pp 271-285, 1986.
408. Várady L., Nagy J., **Knoll J.**: Electrophoretic studies on human satietins. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.3, Sect.6., Pergamon Press, Akadémiai Kiadó, Budapest, pp 287-292, 1986.
409. Zsilla G., Székely A.M., **Knoll J.**: Modulation of neurotransmitter receptors and recognition sites by repeated doses of (-)deprenyl. In: Advances in pharmacological research and practice. (Gen. Eds.: Knoll J., Kelemen K.) Vol.2, Sect.3., Pergamon Press, Akadémiai Kiadó, Budapest, pp 57-65, 1986.
410. Zsilla G., Székely A.M., **Knoll J.**: Influence on neurotransmitter turnover rate and receptor density by repeated, low doses of (-)deprenyl. In: Modulation of Central and Peripheral Transmitter Function. (Eds.: Biggio G., Spano P.F., Toffano G., Gessa G.I.), Liviana Press, Padova, pp 443-446, 1986.
411. **Knoll J.**: Satietins, alpha-1-glycoproteins in human plasma with potent, long lasting and selective anorectic activity. *Med. Res. Rev.* 7, 107-144, 1987.
412. **Knoll J.**: R-(-)Deprenyl (Selegiline, Movergan^R) facilitates the activity of the nigrostriatal dopaminergic neuron. *J. Neural Transm., Suppl.*, 25, 45-66, 1987.
413. **Knoll J.**, Gyires K., Hermeicz I.: 1,6-Dimethyl-4-oxo-1,6,7,8,9,9a-hexahydro-4H-pyrido(1,2a)-pyrimidine-3-carboxamide (Ch-127) protects against the intestinal damage in rats caused by two weeks daily administration of indometacin. *Drugs Exptl. Clin. Res.* 13, 253-258, 1987.
414. **Knoll J.**: Satietins, a family of endogenous enorexogenic glycoproteins. In: Trends in the pharmacology of neurotransmission. (Eds.: Stoichev T., Staneva-Stoicheva S., Radonirov R., Todorov S., Ovcharov R.), Bulgarian Acad. Sci., Sofia, pp 137-143, 1987.
415. **Knoll J.**: Angiohypotensin: an interpretation why peripheral resistance in essential hypertension is increased. In: Cardiovascular Pharmacology '87'. (Ed.: Papp Gy.), Akadémiai Kiadó, Budapest, pp 245-251, 1987.
416. **Knoll J.**: Gyógyszertan (Tankönyv, hatodik, átdolgozott kiadás, 1-2 kötet). Medicina Könyvkiadó, Budapest, pp 1-1163, 1987. (Handbook of Pharmacology, revised 6th edition)

417. Kelemen K., **Knoll J.**: Central nervous system stimulants and anorectic agents. In: Side effects of drugs. Annual II. (Ed.: Dukes M.N.G.), Elsevier, Amsterdam, pp 1-11, 1987.
418. Abdorubo A., **Knoll J.**: The effect of various MAO-B inhibitors on rabbit arterial strip response to tyramine. *Pol. J. Pharmacol. Pharm.* 40, 673-683, 1988.
419. Fürst S., Gyires K., **Knoll J.**: The analgesic profile of rimazolium as compared to different classes of pain killers. *Arzneim. Forsch. Drug. Res.* 38, 552-557, 1988.
420. Fürst S., Wágner T., **Knoll J.**: Azidomorphines and hetrogenous opiate receptors. *Pol. J. Pharmacol. Pharm.* 40, 627-634, 1988.
421. Gyarmati S., Tímár J., Knoll B., **Knoll J.**: Serotonin-mediated behavior in rats chronically treated with (-)deprenyl. *Pol. J. Pharmacol. Pharm.* 40, 667-671, 1988.
422. **Knoll J.**: Endogenous anorectic agents - satietins. *Ann. Rev. Pharm. Toxicol.* 28, 247-268, 1988.
423. **Knoll J.**: Extension of life span of rats by long-term (-)deprenyl-treatment. *Mount Sinai J. Med.* 55, 67-74, 1988.
424. **Knoll J.**: The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl. *Mech. Aging Dev.* 46, 237-262, 1988.
425. Miklya I., **Knoll J.**: A new sensitive method which unlike the Vogel test detects the anxiolytic effect of tofizopam. *Pol. J. Pharmacol. Pharm.* 40, 561-572, 1988.
426. Tímár J., Knoll B., **Knoll J.**: The effect of (-)deprenyl on different changes induced by dopamine agonists in the rat. *Pol. J. Pharmacol. Pharm.* 40, 659-666, 1988.
427. Dalló J., Yen T. T., Faragó I., **Knoll J.**: The aphrodisiac effect of (-)deprenyl in non copulator male rats. *Pharm. Res. Comm.*, 20, Suppl., 1, 25-26, 1988.
428. Friedmann T., **Knoll J.**: Classification of opioid receptprs in the nictitating membrane of the cat. *Pharm. Res. Comm.*, 20, Suppl., 1, 123-124, 1988.
429. Gyarmati S., Tímár J., Knoll B., **Knoll J.**: Influence of repeated administration of (-)deprenyl on serotonin syndrome in rats. *Pharm. Res. Comm.*, 20, Suppl., 1, 145-146, 1988.
430. Gyires K., **Knoll J.**: Antiphlogistic action and mucosal protection. *Pharm. Res. Comm.*, 20, Suppl., 1, 13-14, 1988.
431. Knoll B., Tímár J., **Knoll J.**: Amphetamine-derived potent psychostimulants devoid of biogenic amine releasing properties. *Pharm. Res. Comm.*, 20, Suppl., 1, 119-120, 1988.

432. **Knoll J.**: Correlation between the status of striatal dopamine, sexual activity and lifespan in male rats. Longevity study with (-)deprenyl. *Pharm. Res. Comm.*, 20, Suppl., 1, 1-2, 1988.
433. Miklya I., Rácz D., **Knoll J.**: Pharmacological evidence that the anxiolytic effect of tofisopam is related to a subgroup of benzodiazepine receptors. *Pharm. Res. Comm.*, 20, Suppl., 1, 113-114, 1988.
434. Tímár J., Knoll B., **Knoll J.**: Further evidence that (-)deprenyl acts selectively on the striatal dopaminergic system. *Pharm. Res. Comm.*, 20, Suppl., 1, 21-22, 1988.
435. Zsilla G., **Knoll J.**: Abolishment of rat striatal dopamine receptor supersensitivity by repeated doses of (-)deprenyl. *Pharm. Res. Comm.*, 20, Suppl., 1, 23-24, 1988.
436. Fürst S., Friedmann T., **Knoll J.**: Studies on the interaction of azidomorphine with different classes of opiate receptors. In: *Regulatory Roles of Opioid Peptides*. (Eds.: Illés, P., Farsang, C.) Springer Verlag, Berlin, 358-377, 1988.
437. Gyires K., Hermeicz I., **Knoll J.**: Comparison of the effect of prostaglandin synthesis inhibitors and pyridopyrimidine derivatives on different ulcer models. In: *New Pharmacology Ulcer Disease Experimental and New Therapeutic Approach*. (Eds.: Szabó, S., Mózsik, Gy.), Elsevier, Amsterdam, 489-504, 1988.
438. Kelemen K., **Knoll J.**: Central nervous system stimulants and anorectic agents. In: *Side Effects of Drugs, Annual 12*. (Eds.: Dukes, M. N. G., Beeley, L.), Elsevier, Amsterdam, 1-7, 1988.
439. **Knoll J.**: Endogenous anorectic agents - satietins. In: *Molecular Basis of Action of Drugs and Toxic Substances*. (Eds.: Singer, T. P., Castagnoli, N., Wang, C. C.), Walter de Gruyter, Berlin, 78-93, 1988.
440. **Knoll J.**: R-(-)Deprenyl (Selegilin, Movergan) fördert die Aktivität der nigro-striären dopaminergen Neuronen. In: *Morbus Parkinson. Selegilin, Movergan. Ein neues Therapiekonzept*. (Eds.: Riederer, P., Pruntek, H.), Springer Verlag, Wien, 47-70, 1988.
441. **Knoll J.**: Angiohypotensin: selective inhibitor of the release of noradrenaline from vascular smooth muscle. In: *Basic Aspects and Peripheral Mechanisms*. Alan R. Liss, Inc., 13-16, 1988.
442. Gyires K., Hermeicz I., **Knoll J.**: The effect of some anti-ulcer agents on the early vascular injury of gastric mucosa induced by ethanol in rats. *Acta Physiol. Hung.* 73, 149-154, 1989.
443. **Knoll J.**: The pharmacology of selegiline /(-)deprenyl/. New aspects. *Acta Neurol. Scand.* 126, 83-91, 1989.

444. **Knoll J.**, Dalló J., Yen T.T.: Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl. *Life Sci.* 45, 525-531, 1989.
445. Gyarmati S., Hársing L.G.Jr., **Knoll J.:** Biochemical evidence that (-)deprenyl has no effect on the mesolimbic dopamine system. *Behav. Pharmacol.* 1, Suppl., 1, 33-34, 1989.
446. Timár J., Knoll B., **Knoll J.:** (-)Deprenyl-derived new spectrum psychostimulants. *Naunyn-Schmied. Arch. Pharmacol.* 340, Suppl., R-54, 1989.
447. Timár J., Knoll B., **Knoll J.:** (-)Deprenyl affects the nigrostriatal but not the mesolimbic effect of dopamine agonists. *Behav. Pharmacol.* 1, Suppl., 1, 40, 1989.
448. Gyires K., Hermecz I., **Knoll J.:** Recent data on the inhibition of mucosal damage by pirido-pyrimidines. In: *Ulcer Disease: New Aspects of Pathogenesis and Pharmacology.* (Eds.: Szabó, S., Mózsik, G.), CRC Press, Boca Raton, 381-391, 1989.
449. Kalász H., Kerecsen L., **Knoll J.:** Chromatographic studies on the binding and metabolism of (-)deprenyl. *J. Chromatogr.* 499, 589-599, 1990.
450. Dalló J., Yen T.T., **Knoll J.:** The aphrodisiac effect of (-)deprenyl in male rats. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. *Acta Phys. Hung.* 75, Suppl., 75-76, 1990.
451. Faragó I., Miklya I., **Knoll J.:** The dose-related hypotensive effect of highly purified bovine liver angiohypotensin in narcotized normotensive rats. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. *Acta Phys. Hung.* 75, Suppl., 115-116, 1990
452. Gyarmati S., Timár J., Tekes K., **Knoll J.:** Repeated administration of (-)deprenyl leaves the mesolimbic dopaminergic activity unchanged. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. *Acta Phys. Hung.* 75, Suppl., 133-134, 1990.
453. Knoll B., Yasar S., Faragó I., Kovács I., **Knoll J.:** 1-Phenyl-2-propyl-aminopentane.HCL (MK-306): A deprenyl-derived new spectrum psychostimulant. IIth Int. Congr. of Pharmacol., Amsterdam, 1990. *Eur. J. Pharmacol.* 183, 1464, 1990.
454. Knoll B., Yasar S., Timár J., **Knoll J.:** A (-)deprenyl-derived new spectrum psychostimulant. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. *Acta Phys. Hung.* 75, Suppl., 173-174, 1990.
455. Kovács I., Miklya I., **Knoll J.:** The selectivity of a highly purified bovine liver angiohypotensin towards resistance vessels. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. *Acta Phys. Hung.* 75, Suppl., 179-180, 1990.

456. Miklya I., Berényi D., **Knoll J.:** A new spectrum anxiolytic: 3-amino-4-ethylthio-7-Cl-quinoline HCl (EGIS 5278). 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. Acta Phys. Hung. 75, Suppl., 179-180, 1990.
457. Miklya I., Rácz D., Zsilla G., Berényi D., **Knoll J.:** 3-Amino-4-ethylthio-7-Cl-quinoline HCl (EGIS 5278), a benzodiazepine receptor related new spectrum anxiolytic. IIth Int. Congr. of Pharmacol., Amsterdam, 1990. Eur. J. Pharmacol. 183, 1464-1465, 1990.
458. Rácz D., Miklya I., **Knoll J.:** Elaboration of highly purified angiohypotensin preparations from mammalian liver. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. Acta Phys. Hung. 75, Suppl., 179-180, 1990.
459. Timár J., Gyarmati S., Hársing L.G.Jr., Knoll B., **Knoll J.:** Biochemical and behavioural evidences for the selective nigrostriatal action of (-)deprenyl. IIth Int. Congr. of Pharmacol., Amsterdam, 1990. Eur. J. Pharmacol. 183, 1422, 1990.
460. Timár J., Yasar S., Knoll B., **Knoll J.:** Comparison of the effect of (-)deprenyl 1-phenyl-2-propylaminopentane (MK-306) and amphetamine on the striatal and limbic dopaminergic system. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. Acta Phys. Hung. 75, Suppl., 279-280, 1990.
461. Yasar S., Timár J., Knoll B., **Knoll J.:** Comparison of the dependence capacity of amphetamine, MK-306 and deprenyl. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. Acta Phys. Hung. 75, Suppl., 299-300, 1990.
462. Yen T.T., Dalló J., **Knoll J.:** Effect of Dinh lang and (-)deprenyl on survival rate of male rats. 2nd Joint Meeting of Italian and Hungarian Pharmacological Societies, Budapest, 1990. Acta Phys. Hung. 75, Suppl., 301-302, 1990.
463. **Knoll J.:** A központi idegrendszer gyógyszerterana. In: Gyógyszerteran (Ed.: Knoll, J.), Medicina Könyvkiadó, Budapest, 183-265, 1990.
464. **Knoll J.:** Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. In: Advances in Neurology. Vol. 53: Parkinson's disease: anatomy, pathology, and therapy. (Eds.: Streifler, M. M., Korczyn, A. D., Melamed, E., Youdim, M.H.B.), Raven Press, New York, 425-429, 1990.
465. **Knoll J.:** The enantioselective pharmacological spectrum of levo-deprenyl. In: Problems and Wonders of Chiral Molecules (Ed.: Simonyi, M.), Akadémiai Kiadó, Budapest, 255-65, 1990.
466. Berényi S., Makleit S., Hosztafi S., Fürst S., Friedmann T., **Knoll J.:** Synthesis of a new morphine derivative with anorexogenic activity. Med. Chem. Res. 1, 185-190, 1991.

467. Timár J., Knoll B., Yasar S., **Knoll J.**: Repeated (-)-deprenyl treatment fails to induce amphetamine-like behavioural effect. *Biol. Psychiatr.* 29, 11S, P-04-10 (1991)
468. Zsilla G. and **Knoll J.**: Neurochemical effects on rat brain adrenergic system by repeated administration of (-)deprenyl. *Biol. Psychiatr.* 29, 11S, P-26-41 (1991)
469. **Knoll J.**: A review of the pharmacology of selegiline. *Acta Neurol. Scand.* (Suppl.) Denmark 84/136, 44-59 (1991)
470. Dalló J., **Knoll J.**: Effect of (-)-parafluoro-deprenyl on survival and copulation in male rats. *Acta. Physiol. Hung.* 79(2), 125-129, 1992.
471. Gyarmati S., Timár J., Knoll B., **Knoll J.**: The lack of change in sensitivity of dopamine and muscarine receptors after repeated treatment of (-)deprenyl. *Clin. Neuropharm.*, 15 (1), 600, 1992.
472. Knoll B., Timár J., **Knoll J.**: Analysis of the mechanism of the psychostimulant effect of 1-phenyl-2-propylamino-pentane (PPAP). *Pharmacol. Res.* 25 (2), 48-49, 1992.
473. **Knoll J.**: (-)Deprenyl-medication: A strategy to modulate the age-related decline of the striatal dopaminergic system. *J. Am. Geriatr. Soc.*, 40, 839-847, 1992.
474. **Knoll J.**: Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. *Med. Res. Rev.* 12, 505-524, 1992.
475. **Knoll J.**: The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: A personal view. *Pharmacol. Toxicol.* 70, 317-321, 1992.
476. **Knoll J.**, Knoll B., Török Z., Timár J., Yasar S.: The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP) a deprenyl-derived new spectrum psychostimulant. *Arch. Int. Pharmacodyn. Ther.* 316, 5-29, 1992.
477. **Knoll J.**, Tóth V., Kummert M., Sugár J.: (-)Deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. *Mech. Ageing Dev.* 63, 157-163, 1992.
478. Miklya I., Rácz D., **Knoll J.**: Preparation of highly purified bovine liver angiohypotensin by HPLC. *Pharmacol. Res.* 25 (2), 146-147, 1992.
479. Rácz D., Miklya I., **Knoll J.**: Analysis of bovine liver angiohypotensin (AH) with HPLC purity on smooth muscle preparations. *Pharmacol. Res.* 25(2), 162-163, 1992.
480. Timár J., Gyarmati S., Knoll B., **Knoll J.**: Some behavioural effects of (-) and (+)deprenyl and amphetamine enantiomers: a comparative study. *Pharmacol. Res.* 25(2), 87-88, 1992.

481. Timár J., Knoll B., Gyarmati S., **Knoll J.**: Differences in the behavioural effect of (-)deprenyl enantiomers. *Clin. Neuropharm.*, **15**(1), 600, 1992.
482. Timár J., Knoll B., **Knoll J.**: (-)Deprenyl (Selegiline) is devoid of amphetamine-like behavioural effects in rats. *Acta Physiologica Hungarica* 79, 131-137, 1992
483. Tóth V., Kummert M., Sugár J., **Knoll J.**: (1992) A procedure for measuring neuromelanin in neurocytes by a TV-image analyser. *Mech Ageing Dev* 63:215-221
484. Yen T.T., **Knoll J.**: (1992) Extension of lifespan in mice treated with *Dinh lang* (*Policias fruticosum* L.) and (-)deprenyl. *Acta Physiol Hung* 79:119-124
485. Gyarmati S., Timár J., Knoll B., **Knoll J.**: Reduction of learned helplessness by (-)deprenyl. *Eur. Neuropsychopharmacol.* 3, 346, 1993.
486. **Knoll J.**: Long term selegiline treatment prevents age-related nigral changes. *J. Neurochem.*, 61, S 116, 1993.
487. **Knoll J.**: The pharmacological basis of the beneficial effect of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. *J. Neural Transm.* 40, 69-91, 1993.
488. Timár J., Gyarmati S., Knoll B., Barna L., **Knoll J.**: (-)Deprenyl - lack of inducing place preference conditioning in rats. *Eur. Neuropsychopharmacol.* 3, 412, 1993.
489. Timár J., Gyarmati S., Tekes K., Hársing G.L., **Knoll J.**: Further proof that (-)deprenyl fails to facilitate the mesolimbic dopaminergic activity. *Pharm. Biochem. Behav.* 46, 705-14, 1993.
490. **Knoll J.**: The pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases. In: *Inhibitors of monoamine oxidase B. pharmacology and clinical use in neuro-degenerative disorders* (Ed. Szelenyi, I.) Birghauser Verlag. Basel. pp. 145-168, 1993.
491. **Knoll J.**: Some clinical implication of MAO-B inhibition. In: *Monoamine oxidase: basic and clinical aspects.* (Eds. Yashura, H. Parvez, S H. Oguchi, K. Sandler, M. Nagatsu, T.) VSP Utrecht, The Netherlands, pp. 197-217, 1993.
492. **Knoll J.**: The satietin family of endogenous anorectics. In: *Endocrine and nutritional control of basic biological functions.* Eds. Lehner. H et.al. Hogrefe and Huber Publishers, Seattle, pp. 125-131, 1993.
493. Gyarmati Zs., Timár J., Barna L., Knoll B., **Knoll J.**: Reversal of shuttle-box deficit by PPAP. *European Neuropsychopharmacology* **4**, 298-299, 1994
494. Gyarmati Zs, Timár J, Knoll B, **Knoll J.**: Reversal of inescapable footshock-induced shuttle - box deficit by (-)deprenyl. *Neurobiology*, **2**, 54, 1994.

495. **Knoll J.:** Memories of my 45 years in research. *Pharmacol. & Toxicol.* **75**, 65-72, 1994
496. **Knoll J.,** Miklya I.: Multiple small dose administration of (-) deprenyl enhances catecholaminergic activity and diminishes serotonergic activity in the brain and these effects are unrelated to MAO-B inhibition. *Arch. Int. Pharmacodyn. Ther.* **328**, 1-15, 1994.
497. **Knoll J.,** Yen T.T., Miklya I.: Sexually low performing male rats dies earlier than their high performing peers and (-) deprenyl treatment eliminates this difference. *Life Sci.* **54**, 1047-1057, 1994
498. **Knoll J.:** Angiohypotensin. In: *Handbook of experimental pharmacology*. Vol. 111 *Pharmacology of smooth muscle*. (Eds. Szekeres, L., Papp, Gy.) Springer-Verlag. Berlin, pp 227-242, 1994.
499. Gyarmati Zs., Timár J., Barna L., **Knoll J.:** Effect of (-)deprenyl on PEA-induced activity in rats. *Neurobiology*, **3**, 57, 1995
500. Miklya I., **Knoll J.:** Single, small dose administration of (-)methamphetamine (MA) and (-)deprenyl (D) , in contrast to (+)MA enhances catecholaminergic activity and diminishes serotonergic activity in the brain stem of rats. (EPHAR) First European Congress of Pharmacology, Milan, Italy, June 16-19, 1995. *Pharmacological Reserach* **31**. Suppl. 351, 1995
501. **Knoll J.:** Rationale for (-) deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. *Biomed Pharmacother* **49**, 187-195, 1995
502. **Knoll J.,** Miklya, I.: Enhanced catecholaminergic and serotonergic activity in rat brain from weaning to sexual maturity: Rationale for prophylactic (-) deprenyl (selegiline) medication. *Life Sciences*, **56**(8), 611-620, 1995
503. **Knoll J.:** Rationale for (-) deprenyl (Selegiline) therapy in Parkinson's disease and Alzheimer's disease / Razões da terapêutica com (-) deprenil (Selegilina) na doença de Parkinson e na doença de Alzheimer. *Rev. Bras. Neurol* **31**(3):131-138, 1995
504. **Knoll J.:** Rationale for (-) deprenyl (Selegiline) therapy in Parkinson's disease and Alzheimer's disease / Razões da terapêutica com (-) deprenil (Selegilina) na doença de Parkinson e na doença de Alzheimer *Rev Bras Neurol* **31**(3)131-138, 1995
505. Czurkó A., Faludi B., Karádi Z., Vida I., Niedetzky C., **Knoll J.,** Lénárd L.: Responses of forebrain neurons to the MAO-B blocker L-deprenyl. *Brain Res. Bull.* **36**(3), 241-249, 1995
506. **Knoll J.:** (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment. *Biomed. Pharmacother.* **50**, 315-317, 1996

507. **Knoll J.**, Knoll B., Miklya I.: High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers. *Life Sci.* **58**, 945-952, 1996
508. **Knoll J.**, Miklya I., Knoll B., Markó R., Rácz D.: Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain. *Life Sci.* **58**, 2101-2114, 1996
509. **Knoll J.**, Miklya I., Knoll B., Markó R., Kelemen K.: (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, (-)PPAP, act primarily as potent stimulants of action potential - transmitter release coupling in the catecholaminergic neurons. *Life Sci.* **58**, 817-827, 1996
510. **Knoll J.**: Sexual performance and longevity. *Experimental Gerontology* **32**, 539-552, 1997
511. **Knoll J.**: The history of (-)deprenyl the first selective inhibitor of type-B monoamine oxidase. *Voprosy Meditsinskoi Khimii* **43**, 482-493, 1997
512. **Knoll J.**: (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. *Pharmacol. Toxicol.* **82**, 57-66, 1998.
513. **Knoll J.**: Deprenyl, the first catecholaminergic activity enhancer. *The Rise of Psychopharmacology and The Story of CINP* (Eds.: Ban, T.A., Healy, D., Shorter, E.) Animula, 91-95, 1998.
514. **Knoll J.**, Yoneda F., Knoll B., Ohde H., Miklya I.: (-)1-(Benzofuran-2-yl)-2-propylaminopentane, /(-)BPAP/, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Brit. J. Pharmacol.* **128**, 1723-1732, 1999
515. **Knoll J.**: Outlines of a drug strategy to slow brain aging. *Neuropsychopharmacologia Hungarica* **4**, 151-170, 2000
516. **Knoll J.**: (-)Deprenyl (Selegiline): past, present and future. *Neurobiology* **8**, 179-199, 2000
517. **Knoll J.**, Miklya I., Knoll B., Dalló J.: Sexual hormones terminate in the rat the significantly enhanced catecholaminergic /serotonergic tone in the brain characteristic to the post-weaning period. *Life Sciences* **67**, 765-773, 2000
518. **Knoll J.**: The psychopharmacology of life and death in *The Psychopharmacologists III, Interviews by Dr. David Healy*; Arnold, London, Oxford University Press, New York; pp 81-110, 2000
519. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., **Knoll J.**: Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Bioorg. Med. Chem.* **9**, 1197-1212, 2001

520. Oka T., Yasusa T., Ando T., Watanabe M., Yoneda F., Ishida T., **Knoll J.**: Enantio-selective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer. *Bioorg. Med. Chem.* 9, 1213-1219, 2001
521. Shimazu S., Takahata K., Katsuki H., Tsunekawa H., Tanigawa A., Yoneda F., **Knoll J.**, Akaike A.: (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. *Eur. J. Pharm.*, 421, 181-189, 2001
522. **Knoll J.**: Antiaging compounds: (-)Deprenyl (Selegiline) and (-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)BPAP, a selective highly potent enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *CNS Drug Reviews* 7, 317-345, 2001
523. Miklya I., Knoll B., **Knoll J.**: Miért volt a (-)-deprenil (Selegilin, Jumex) hatékony és az α -tokoferol hatástalan a DATATOP vizsgálatban? *Neuropsychopharmacologia Hungarica* 4:168-172, 2002
524. Magyar K., Lengyel J., Bolehovszky A., Knoll B., Miklya I., **Knoll J.**: The fate of (-)-1-(benzofuran-2-yl)-2-propylaminopentane HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain. *European Journal of Drug Metabolism and Pharmacokinetics* 27: 157-161, 2002
525. **Knoll J.**, Miklya I., Knoll B.: Stimulation of the catecholaminergic and serotonergic neurons in the rat brain by *R*-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, (-)-BPAP. *Life Sciences* 71:2137-2144 (2002)
526. **Knoll J.**, Miklya I., Knoll B., Yasusa T., Shimazu S., Yoneda F.: 1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged. *Life Sciences* 71:1975-1984 (2002)
527. Shimazu S., Tamashiro A., Yoneda F., **Knoll J.**: L-DOPA-sparing effect of *R*-(-)-1-(benzofuran-2-yl)-2-propylaminopentane in reserpine-pretreated rats. *Life Sciences* 72: 1413-1419, 2003.
528. Miklya I., Knoll B., **Knoll J.**: A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (Selegiline), α -tocopherol was ineffective in the DATATOP study. *Life Sciences* 72:2641-2648, 2003
529. Shimazu S., Tanigawa A., Sato N., Yoneda F., Hayashi K., **Knoll J.**: Enhancersubstances: selegiline and *R*-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. *Life Sciences* 72:2785-2792, 2003

530. Miklya I., **Knoll J.**: Analysis of the effect of (-)-BPAP, a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. *Life Sciences* 72:2915-2921, 2003
531. Miklya I., Knoll B., **Knoll J.**: An HPLC tracing of the enhancer regulation in selected discrete brain areas of food deprived rats. *Life Sciences* 72:2923-2930, 2003
532. **Knoll J.**: Enhancer regulation/Endogenous and Synthetic Enhancer Compounds: A Neurochemical Concept of the Innate and Acquired Drives. *Neurochemical Research* 28:1187-1209, 2003
533. **Knoll J.**: The mechanism of the anti-aging effect of Deprenyl. *Antiaging Bulletin* 4:26-36, 2003
534. **Knoll J.**: Agytörzsi és agykérgi enhancer reguláció. A veleszületett és szerzett hajtóerők neurokémiai koncepciója. *Magyar Tudomány* 4:418-432, 2004
535. **Knoll J.**: Issekutz Béla (1886-1979) Esti beszélgetés. *Magyar Gyógyszerkutatók Portréi*. Szerkesztők: Takácsné Novák Krisztina, Hermez István. Magyar Gyógyszerésztudományi Társaság, Budapest, 2005, 137-147
536. **Knoll J.**: The Brain and Its Self. A Neurochemical Concept of the Innate and Acquired Drives. Springer, Berlin, Heidelberg, New York, 2005, pp 1-176
537. **Knoll J.**: Az agy és tudata. A veleszületett és szerzett hajtóerők neurokémiai koncepciója. Akadémiai Kiadó, Budapest, 266 oldal, 2006
538. **Knoll J.**: The neurotransmitter era in neuropsychopharmacology. Reflections of a pharmacologist. In: The neurotransmitter era in neuropsychopharmacology. Eds.: T.A. Ban and R.U. Udabe, Editorial Polemos, Buenos Aires, Argetina, 2006, Chapter 15. pp.211-216.
539. **Knoll J.**: Shattering the Barriers of Maximum Life Span: An Interview with Dr. Joseph Knoll. In: *Mavericks of Medicine* by David J. Brown, Smart Publication, Petaluma, California, 2006
540. **Knoll József**, Semmelweis Kiadó, Budapest, 91 oldal, 2006. INTERJU az „Apáink jönnek velünk szembe” sorozatban.
541. **Knoll J.**: Szerzett hajtóerők. A társadalmi létforma születésért és fejlődéséért felelős agykérgi mechanizmus. *Neuropsychopharmacologia Hungarica* IX/3; 151-166, 2007.
542. **Knoll J.**: Az emberiség jövője. A társadalomteremtő agykérgi mechanizmusok elemzésére épített jövőkép. Semmelweis Kiadó, Budapest, 329 oldal, 2010.
543. **Knoll J.**: interviewed by Ban TA, *An Oral History of Neuropsychopharmacology – The First Fifty Years: Peer Interviews* (Thomas A

Ban editor), Volume 3 – Neuropharmacology (Fridoline Sulser, volume editor).
Nashville: American College of Neuropsychopharmacology; 2011. pp. 297-328

544. **Knoll J.:** How Selegiline ((-)-Deprenyl Slows Brain Aging. Bentham Science
Publishers, 2012. E-book, pp 1-142

Joseph Knoll
January 1, 2015